Monocytic Cells Mediate Granulocyte-Colony Stimulating Factor-Induced Mobilization of Hematopoietic Stem and Progenitor Cells by Rao, Mahil
Washington University in St. Louis
Washington University Open Scholarship
All Theses and Dissertations (ETDs)
Spring 3-4-2013
Monocytic Cells Mediate Granulocyte-Colony
Stimulating Factor-Induced Mobilization of
Hematopoietic Stem and Progenitor Cells
Mahil Rao
Washington University in St. Louis
Follow this and additional works at: https://openscholarship.wustl.edu/etd
Part of the Neuroscience and Neurobiology Commons
This Dissertation is brought to you for free and open access by Washington University Open Scholarship. It has been accepted for inclusion in All
Theses and Dissertations (ETDs) by an authorized administrator of Washington University Open Scholarship. For more information, please contact
digital@wumail.wustl.edu.
Recommended Citation
Rao, Mahil, "Monocytic Cells Mediate Granulocyte-Colony Stimulating Factor-Induced Mobilization of Hematopoietic Stem and
Progenitor Cells" (2013). All Theses and Dissertations (ETDs). 1067.
https://openscholarship.wustl.edu/etd/1067
	  WASHINGTON UNIVERSITY IN ST. LOUIS 
 
 
Division of Biology & Biomedical Sciences 
Neurosciences 
 
 
Dissertation Examination Committee: 
Daniel C. Link, Chair 
Kyunghee Choi 
Mary Dinauer 
Timothy Ley 
Fanxin Long 
Deborah Novack 
 
 
 
 
 
Monocytic Cells Mediate Granulocyte-Colony Stimulating Factor-Induced Mobilization of 
Hematopoietic Stem and Progenitor Cells 
 
by 
 
Mahil Rao 
 
 
 
 
 
 
 
A dissertation presented to the  
Graduate School of Arts and Sciences 
of Washington University in  
partial fulfillment of the  
requirements for the degree  
of Doctor of Philosophy 
 
 
 
May 2013 
 
St. Louis, Missouri 	   	  
	   	  	  	  	  	  	   	  	  	  
 
 © Copyright 2013 by Mahil Rao. 
All rights reserved. 	  
	  	   ii 
TABLE OF CONTENTS	  
 
List of Figures .................................................................................................................... iii 
 
 
List of Tables ..................................................................................................................... iv 
 
 
Acknowledgements ............................................................................................................. v 
 
 
Abstract of the Dissertation ............................................................................................... vi 
 
 
Chapter 1: Introduction ....................................................................................................... 1 
 
 
Chapter 2: Expression of the G-CSF receptor in monocytic cells is sufficient to mediate 
hematopoietic progenitor mobilization by G-CSF in mice ............................................... 10 
 
Tables and Figures ................................................................................................ 28 
 
 
Chapter 3: Osteoclasts are not required for G-CSF-induced HSPC mobilization ............ 37 
 
Figures ................................................................................................................... 54 
 
 
Chapter 4: Summary and Future Directions ..................................................................... 61 
 
 
Literature Cited ................................................................................................................. 72 
 
	  	   iii 
LIST OF FIGURES 
2.1  Neutrophil number in the bone marrow correlates poorly with G-CSF-induced HSPC 
mobilization  .............................................................................................................. 29 
2.2  G-CSF-induced HSPC mobilization is normal in Rag1-/- and NOD/scid/IL-2γnull mice 
 ................................................................................................................................... 30 
2.3  G-CSFR expression is mainly restricted to monocytic cells in CD68:G-CSFR mice      
 ................................................................................................................................... 31 
2.4  G-CSF-induced HSPC mobilization is normal in CD68:G-CSFR mice  .................. 32 
2.5  G-CSF treatment leads to a loss of monocytic cells from the bone marrow  ............ 33 
2.6  Macrophages support the growth of mature osteoblasts in vitro  .............................. 34 
Supplemental Figure 2.1  B-lymphocyte chimerism in mixed Csf3r-/- chimeras  .......... 35 
Supplemental Figure 2.2  Absolute number of neutrophils in mixed Csf3r-/- chimeras       
 ................................................................................................................................... 36 
3.1  Osteoclast loss does not lead to mobilization of HSPCs  .......................................... 54 
3.2  Osteoclasts are not required for G-CSF-induced mobilization of HSPCs  ................ 55 
3.3  Ablation of myeloid dendritic cells augments the mobilization response to G-CSF  56 
3.4  Ablation of myeloid dendritic cells augments the G-CSF-induced peripheral leukocytosis 
and suppression of mature osteoblasts but not total bone marrow CXCL12 production 
 ................................................................................................................................... 57 
3.5  G-CSF administration reduces the frequency of myeloid dendritic cells in the bone marrow 
 ................................................................................................................................... 58 
Supplemental Figure 3.1  Administration of a single dose of 100 µg OPG-Fc is sufficient to 
ablate osteoclasts  ...................................................................................................... 59 
Supplemental Figure 3.2  Inhibition of osteoclast activity with zoledronate (Zometa) results in 
mobilization and augments the mobilization response to G-CSF without a significant 
reduction in the frequency of TRAP+ cells  .............................................................. 60 
	  	   iv 
LIST OF TABLES 
2.1  Peripheral blood counts of CD68:G-CSFR mice  ...................................................... 28 
4.1  Expression of genes that regulate osteoblast number and/or activation  ................... 67 	  	   	  
	  	   v 
ACKNOWLEDGEMENTS 
 
 
 
 
This work was supported by a grant from the National Institutes of Health  
 
(R01 HL60772, to Daniel C. Link) 	  	  	   	  
	  	   vi 
ABSTRACT OF THE DISSERTATION 
 
Monocytic Cells Mediate Granulocyte-Colony Stimulating Factor-Induced Mobilization of 
Hematopoietic Stem and Progenitor Cells 
 
by 
 
Mahil Rao 
 
Doctor of Philosophy in Biology & Biomedical Sciences 
Neurosciences 
 
Washington University in St. Louis, 2013 
 
Professor Daniel C. Link, Chairperson 
 
 
In the normal, healthy adult, hematopoiesis occurs primarily in the bone marrow. As such, at 
steady state, a majority of hematopoietic stem and progenitor cells (HSPCs) are tightly held 
within specialized areas of the bone marrow collectively referred to as the ‘hematopoietic stem 
cell niche.’ In response to various forms of stress, such as infection or hemorrhage, or following 
administration of a variety of pharmacologic agents, niche function is altered and HSPCs are 
released into the peripheral circulation through a process known as mobilization. Granulocyte-
colony stimulating factor (G-CSF), a hematopoietic growth factor, is the most widely-used 
mobilizing agent clinically. However, the mechanisms by which G-CSF elicits HSPC 
mobilization are not well-understood. The experiments described herein are directed towards 
understanding the mechanism by which G-CSF elicits mobilization as a means to understanding 
regulation of HSPC trafficking between the bone marrow and periphery. We first focused on 
identifying the hematopoietic lineage directly targeted by G-CSF in the initiation of HSPC 
mobilization. Using a mouse model in which the G-CSF receptor is selectively expressed on 
monocytic cells, we demonstrate that G-CSF signaling in monocytic cells is sufficient for a 
normal mobilization response. Subsequent studies were designed to identify which of the three 
	  	   vii 
major cell types within the monocytic lineage – bone marrow macrophages, osteoclasts, and 
myeloid dendritic cells – are critical for retention of HSPCs within the bone marrow and for the 
mobilization response to G-CSF. We demonstrate that loss of myeloid dendritic cells does not 
abrogate the mobilization response to G-CSF and that pharmacologic ablation of osteoclasts does 
not lead to HSPC release into the periphery. Lastly, we evaluated the importance of selected 
factors produced by monocytes in the mobilization response to G-CSF. We demonstrate that 
hematopoietic loss of osteopontin does not alter the mobilization response to G-CSF. Further 
work will be required to evaluate the role of bone marrow macrophages and myeloid dendritic 
cells in HSPC retention as well as the requirement for osteoclasts in G-CSF-induced 
mobilization. Future studies will be directed at identifying the factors used by monocytic cells to 
communicate with the stromal components of the HSPC niche during G-CSF-induced 
mobilization. 
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CHAPTER 1 
INTRODUCTION 	  	   	  
	  	   2 
In the healthy adult, a majority of hematopoietic stem cells reside within the bone 
marrow. In response to various forms of physiologic stress, such as infection or hemorrhage, 
these cells are released into the peripheral circulation, a process termed ‘hematopoietic stem cell 
mobilization.’ In the late 1980s, it was observed that large numbers of hematopoietic stem and 
progenitor cells could be mobilized through administration of a variety of agents, including 
hematopoietic growth factors (1,2), cytokines, or even cytotoxic agents (3,4). This observation 
proved to be of great clinical utility, as these mobilized HSPCs could be harvested from the 
peripheral blood and used for hematopoietic stem cell transplantation (HSCT) (5-8). 
Granulocyte-colony stimulating factor (G-CSF), a hematopoietic growth factor, is currently the 
most commonly used agent in the clinical setting. G-CSF-mobilized stem cells have emerged as 
the preferred source of stem cells for HSCT, as they are associated with more rapid engraftment, 
a shorter hospital stay, and, in some circumstances, superior overall survival compared to 
unmanipulated bone marrow (9-13). However, when used for autologous transplant in the setting 
of acute myelocytic leukemia, G-CSF-mobilized stem cells are associated with an increased rate 
of relapse (14,15). Furthermore, nearly 20% of stem cell donors fail to mobilize enough 
hematopoietic stem cells for successful HSCT in response to either G-CSF alone or in 
combination with other mobilizing agents (16-18). Thus there is an urgent need to develop novel 
mobilizing agents; the rational design of such agents requires a detailed understanding of the 
mechanisms that regulate stem cell trafficking. 
Despite its widespread clinical use, the mechanisms underlying G-CSF-induced HSPC 
mobilization have not been well-characterized. The studies described herein were designed to 
elucidate the molecular events associated with G-CSF administration as a way to understand 
regulation of HSPC trafficking. We initially focused on a basic question: what cell type is 
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directly targeted by G-CSF in the initiation of the mobilization cascade? The G-CSF receptor (G-
CSFR) is expressed on a number of different stromal and hematopoietic populations (19-21), and 
mice lacking G-CSFR (Csf3r-/-) do not mobilize HSPCs in response to G-CSF (22). To 
determine whether the G-CSF target cell type was contained within the stromal or hematopoietic 
compartments, Liu, et al. constructed a series of chimeric mice using marrow from wild-type and 
Csf3r-/- donors. They observed that wild-type mice reconstituted with Csf3r-/- marrow did not 
mobilize in response to G-CSF, while Csf3r-/- mice reconstituted with wild-type marrow 
exhibited normal mobilization, suggesting that mobilization required G-CSF signaling in the 
hematopoietic but not the stromal compartment (23).  
Within the transplantable hematopoietic compartment there are five major cell types that 
express G-CSFR: neutrophils, monocytes/macrophages, lymphocytes, NK cells, and HSPCs. The 
simplest model predicts that G-CSF acts directly on hematopoietic stem and progenitor cells to 
elicit their mobilization; however, in mixed chimeras of wild-type and Csf3r-/- marrow, both cell 
types mobilize with equal efficiency (23). This suggests that G-CSF does not act directly on 
HSPCs but rather signals through a ‘trans-acting’ factor to elicit HSPC mobilization. The nature 
of this factor is still an area of active investigation. 
There is some evidence implicating neutrophils in G-CSF-induced HSPC mobilization.  
Neutrophils are a major source of proteases, including neutrophil elastase, cathepsin G, and 
MMP-9 (24,25). During G-CSF treatment, neutrophils release these proteases into the bone 
marrow microenvironment (26-32). These proteases, through cleavage of CXCL12 (26,29), c-kit 
(30), and VCAM-1 (31), may contribute to HSPC mobilization.  However, their importance is 
controversial as mice lacking the proteases exhibit a normal mobilization response to G-CSF 
(33-35).  
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HSPC mobilization by the chemokine interleukin-8 (IL-8) is dependent on neutrophils. 
Csf3r-/- mice, which are profoundly neutropenic, fail to mobilize in response to IL-8 (22).  
Moreover, antibody-mediated depletion of neutrophils (using anti-CD11a or anti-Gr-1 
antibodies) abrogated IL-8-induced HSPC mobilization (36,37).  With respect to G-CSF, Pelus 
and colleagues reported that neutrophil depletion using anti-Gr-1 antibodies attenuated G-CSF-
induced HSPC mobilization (34). However, Gr-1 is expressed on both neutrophils and a subset 
of monocytes; thus, a role for reduced monocytes in this phenotype is possible.   
The contribution of lymphocytes to G-CSF-induced HSPC mobilization is also 
controversial. Reca, et al. reported that G-CSF-induced mobilization is impaired in Rag2-/-, 
SCID, and Jh mice, and that this deficit can be reversed through administration of complement-
inducing immunoglobulin (38).  In contrast, Katayama, et al. reported that Rag1-/- mice and IL-
7R-/- mice exhibited a normal mobilization response to G-CSF (21). The basis for these 
discrepancies remains unclear.  Though all of these mouse lines share deficits in B- and T-
lymphopoiesis, it is conceivable that subtle differences in the strains could account for the 
variations observed.  
Several lines of evidence indicate that monocyte lineage cells in the bone marrow 
contribute to osteoblast homeostasis and HSPC trafficking. Chang, et al, demonstrated that 
macrophages are anatomically juxtaposed with endosteal osteoblasts, forming a “canopy” over 
the osteoblasts at sites of bone formation (39). Moreover, they showed that ablation of monocytic 
cells using the MAFIA transgenic mouse model resulted in a loss of osteoblasts (39). Similarly, 
Winkler et al. recently showed that macrophage ablation using the MAFIA transgenic mouse 
model or through administration of clodronate-loaded liposomes resulted in a loss of osteoblasts 
and HSPC mobilization (40), although we have observed that when MAFIA mice are crossed to 
	  	   5 
Csf3r-/- mice, ablation of macrophages does not result in HSPC mobilization (M.J. Christopher 
and D.C. Link, unpublished data). Finally, Chow, et al. demonstrated that depletion of 
monocytic-lineage cells using a variety of methods is sufficient to induce mobilization of HSPCs 
(41). Together, these data strongly suggest that monocytic cells play an important role in 
retention of HSPCs within the marrow. 
There are at least three distinct bone marrow monocytic cell populations: bone marrow 
resident macrophages, myeloid dendritic cells, and osteoclasts. There is considerable (though 
conflicting) data on the role of osteoclasts in HSPC mobilization.  Kollet and colleagues reported 
that activation of osteoclasts by injection of RANK ligand (RANKL) was associated with 
moderate HSPC mobilization, and inhibition of osteoclasts, either genetically by knocking out 
PTPε or by injecting mice with calcitonin, blunts the mobilization response to G-CSF (42). Of 
note, osteoclasts produce the protease cathepsin K, which can cleave CXCL12 in vitro (42,43).  
On the other hand, other studies indicate that osteoclasts may actually inhibit mobilization, as 
mice that were given pamidronate, an osteoclast-inhibiting bisphosphonate, exhibit increased 
mobilization in response to G-CSF (40,44). G-CSF has also been shown to increase the 
frequency of activated osteoclasts in the marrow, although this occurs several days after the 
onset of mobilization, perhaps suggesting that the two events are unrelated (40,44). 
In contrast to osteoclasts, little is known about the role of bone marrow macrophages and 
myeloid dendritic cells in regulation of HSPC trafficking or in transduction of a mobilization 
signal from G-CSF. Chow, et al. report that the selective ablation of CD169+ macrophages using 
mice expressing diphtheria toxin-receptor under the CD169 promoter is sufficient to elicit HSPC 
mobilization, suggesting that this population provides a critical retention signal for HSPCs (41). 
However, our analysis of CD169 expression in bone marrow cells revealed that it is expressed 
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not only on macrophages but also granulocytic precursors, making it difficult to determine the 
importance of either population on retention of stem cells within the marrow using this approach. 
There is currently no data on the role of myeloid dendritic cells in the regulation of HSPC 
trafficking. The definitive identification of the cell population(s) responsible for HSPC retention 
or transducing the signal from G-CSF requires further study and is, in fact, the major subject of 
this thesis. 
The regulation of hematopoietic stem cell trafficking by more committed hematopoietic 
cells, however, is not direct; rather, it proceeds through one or more stromal populations that are 
part of a specialized structure within the bone marrow known as the ‘hematopoietic stem cell 
niche.’ By definition, a ‘niche’ is a collection of various cell types and secreted soluble factors 
and extracellular matrix that work in concert to provide a highly specialized microenvironment 
for a particular cell type. The idea of a hematopoietic stem cell niche was first proposed by 
Schofeld (45) more than 30 years ago, when it was noted that the distribution of hematopoietic 
stem cells within the marrow was not random. Instead, it was observed that the most primitive 
hematopoietic cells could be found along the endosteal surface of the marrow, with successively 
more committed cells located towards the central axis of the long bone (46-48). These studies 
raised the possibility that cells near the endosteal surface provided an appropriate environment 
wherein hematopoietic stem cells could maintain the balance of self-renewal and differentiation 
required to be able to meet the daily needs of the organism without depleting the stem cell pool. 
Not surprisingly, over the next several years, there was accumulating evidence that osteoblasts 
and osteolineage were important for maintenance of the hematopoietic stem cell pool (49-52). 
Consistent with this idea, induced ablation of mature osteoblasts is sufficient to elicit HSPC 
mobilization (53).  
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Osteoblasts produce a number of factors that promote stem cell quiescence and retention 
within the bone marrow, including VCAM-1, osteopontin, and CXCL12. VCAM-1 is an 
adhesion molecule that binds to VLA-4 expressed on the surface of hematopoietic stem cells 
(54,55). Genetic loss of VCAM-1 leads to constitutive mobilization, while antibodies to either 
VCAM-1 or VLA-4 or administration of a small-molecule inhibitor of VLA-4 all result in 
mobilization (56-58).  
Osteopontin (Spp1) is a secreted, multi-domain glycoprotein produced by many different 
cell types, although the major source of osteopontin in the marrow is osteoblasts. Loss of 
osteopontin does not appear to have a significant impact on osteoblasts themselves, as Spp1-/- 
mice have normal bone development and normal osteoblast numbers (59). However, several 
studies have suggested that osteopontin is important for retention of HSPCs within the endosteal 
niche. For example, osteopontin is expressed only along the endosteal surface, where it binds 
integrins on the surface of HSPCs as well as fibronectin and collagen, thereby tethering HSPCs 
to the extracellular matrix of the endosteal niche (60,61). Consistent with the idea of osteopontin 
serving as a molecular tether, Spp1-/- mice do not retain KLS cells in the marrow as well as their 
wild-type counterparts (60). Several other studies have highlighted a role for osteopontin in the 
maintenance of stem cell quiescence. For example, exogenously-applied osteopontin suppresses 
the growth factor-induced proliferation of HSPCs in vitro (60). Similarly, a greater fraction of 
Spp1-/- KLS cells are cycling at baseline compared to wild-type KLS cells (60). Treatment with 
parathyroid hormone causes a greater increase in HSPC number in Spp1-/- than in their wild-type 
counterparts (61). 
There is accumulating evidence that disruption of CXCR4/CXCL12 signaling is a key 
step in G-CSF-induced HSPC mobilization. CXCL12 (stromal derived growth factor-1, SDF-1) 
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is a chemokine constitutively expressed at very high levels in the bone marrow and is a potent 
chemoattractant for HSPCs. In mice lacking CXCL12 (62) or its major receptor CXCR4 (63) 
there is a failure of the migration of HSPCs from the fetal liver to the bone marrow.  Moreover, 
CXCR4-/- bone marrow chimeras exhibit constitutive mobilization and fail to mobilize HSPCs in 
response to G-CSF (64,65). G-CSF treatment is associated with decreased CXCL12 mRNA and 
protein expression in the bone marrow and decreased CXCR4 expression on HSPCs 
(28,29,64,66).  A potential mechanism for the decreased CXCL12 expression is provided by the 
observation that G-CSF treatment is associated with a marked suppression of osteoblasts 
(21,64,66,67) which are an important source of CXCL12 in the bone marrow (64,66,68-70).  The 
importance of the CXCL12/CXCR4 axis is illustrated by the success of the CXCR4 inhibitor 
plerixafor (AMD3100) to rapidly mobilize HSPCs in humans and mice (71,72).   
Although the studies discussed above demonstrate an important role for CXCL12 in 
regulation of HSPC trafficking, the predominant source of CXCL12 in the marrow is not clear. 
CXCL12 has been reported to be produced by osteoblasts, endothelial cells (68), CXCL12-
abundant reticular cells (70), and even bone itself (21). As previously mentioned, we reported 
that G-CSF treatment was associated with decreased CXCL12 production in osteoblasts (64). 
However, Mendez-Ferrer, et al. report that changes in total bone marrow CXCL12 levels are 
mostly the result of changes in population of nestin-expressing mesenchymal stem cells (73); 
they also report that these nestin-expressing mesenchymal stem cells contribute to formation of a 
separate niche. 
The importance of monocytic cells to survival of niche osteoblasts has been long 
appreciated, as it was demonstrated that macrophages could support the growth of osteoblasts in 
an in vitro culture system (74,75). More recently, Chow, et al. demonstrated that macrophage-
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conditioned media could induce stromal cells to produce CXCL12, thereby promoting retention 
of stem cells within the marrow. Although the exact identity of this factor – the so-called ‘factor 
x’ – remains elusive, it is worth noting that Chow, et al. were able to demonstrate that the ability 
to support macrophages was lost if the macrophage-conditioned media was pre-treated with 
proteinase K, suggesting that ‘factor X’ is indeed a protein (41). 
To summarize, there is considerable evidence suggesting a role for monocytic cells in the 
retention of HSPCs within the bone marrow, although the contributions from other lineages 
cannot yet be excluded. The model that we propose is that at steady state, monocytic cells 
provide trophic support for osteoblasts, which, in turn, provide the necessary signals to keep 
HSPCs within the marrow in a quiescent state. In response to agents such as G-CSF, these 
monocytic cells withdraw their support for osteoblastic cells, leading to their apoptosis and the 
subsequent release of HSPCs into the periphery. Further study will be required to refine our 
concept of which cell type or types participate in the niche and to identify the factor used in 
monocyte/osteoblast communication. 
  
	  	   10 
 
 
 
 
 
 
 
 
 
CHAPTER 2 
EXPRESSION OF THE G-CSF RECEPTOR IN 
MONOCYTIC CELLS IS SUFFICIENT TO 
MEDIATE HEMATOPOIETIC PROGENITOR 
MOBILIZATION BY G-CSF IN MICE  	  	  	  
*The work in this chapter was a joint effort with Dr. Matthew J. Christopher, a former post-
doctoral fellow in the lab, and has been previously published as Christopher, M. J., Rao, M., Liu, 
F., Woloszynek, J. R., & Link, D. C. (2011). Expression of the G-CSF receptor in monocytic 
cells is sufficient to mediate hematopoietic progenitor mobilization by G-CSF in mice. Journal 
of Experimental Medicine, 208(2), 251–260. doi:10.1084/jem.20101700 	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INTRODUCTION 
In the adult human, the majority of hematopoietic stem and progenitor cells (HSPCs) 
reside in specialized environments within the bone marrow collectively referred to as the 
‘hematopoietic stem cell niche.’ The number of HSPCs in the circulation can be markedly 
increased in response to a number of stimuli, including hematopoietic growth factors, 
myeloablative agents, and environmental stresses such as infection. Recently, mobilized stem 
cells have become the preferred cellular source for reconstitution of the bone marrow following 
myeloablative therapy because of their potency, predictability, and safety. Granulocyte-colony 
stimulating factor (G-CSF), a hematopoietic growth factor, is the most commonly used 
mobilizing agent clinically.  However, there is considerable variability in the magnitude of 
HSPCs mobilized by G-CSF, and in about 20% of cases, insufficient cells are mobilized for stem 
cell transplantation (16-18). An understanding of the mechanisms by which G-CSF elicits 
mobilization of HSPCs is critical to the development of novel, more effective mobilizing agents.  
There is accumulating evidence that disruption of CXCR4/CXCL12 signaling is a key 
step in G-CSF-induced HSPC mobilization. CXCL12 (stromal derived growth factor-1, SDF-1) 
is a chemokine constitutively expressed at very high levels in the bone marrow and is a potent 
chemoattractant for HSPCs. In mice lacking CXCL12 (62) or its major receptor CXCR4 (63) 
there is a failure of the migration of HSPCs from the fetal liver to the bone marrow.  Moreover, 
CXCR4-/- bone marrow chimeras exhibit constitutive mobilization and fail to mobilize HSPCs 
in response to G-CSF (64,65). G-CSF treatment is associated with decreased CXCL12 mRNA 
and protein expression in the bone marrow and decreased CXCR4 expression on HSPCs 
(28,29,64,66).  A potential mechanism for the decreased CXCL12 expression is provided by the 
observation that G-CSF treatment is associated with a marked suppression of osteoblasts 
(21,64,66,67), which are an important source of CXCL12 in the bone marrow (64,66,68,69).  
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The importance of the CXCL12/CXCR4 axis is illustrated by the success of the CXCR4 inhibitor 
plerixafor (AMD3100) to rapidly mobilize HSPCs in humans and mice (71,72).   
Through the study of G-CSFR (Csf3r)-/- bone marrow chimeras, we previously showed 
that G-CSFR signaling in hematopoietic cells but not stromal cells is required for HSPC 
mobilization by G-CSF (23). Within the hematopoietic compartment, the G-CSFR is expressed 
on neutrophils, monocytes/macrophages, HSPCs, and a subset of B lymphocytes and NK cells. 
The simplest model suggests that G-CSF directly acts upon HSPCs to induce their mobilization.  
However, strongly arguing against this model, in mixed bone marrow chimeras containing wild-
type and Csf3r-/- HSPCs, both types of cells were mobilized equally after G-CSF treatment (23).   
There is some evidence implicating neutrophils in G-CSF-induced HSPC mobilization.  
During G-CSF treatment, neutrophils release certain proteases into the bone marrow 
microenvironment (26-32). Though controversial, these proteases, through cleavage of CXCL12 
(26,29), c-kit (30), and VCAM-1 (31), may contribute to HSPC mobilization.  A previous study 
reported that depletion of neutrophils using an antibody against Gr-1 (Ly6C/G) results in reduced 
HSPC mobilization by G-CSF (34).  However, Gr-1 is expressed on both neutrophils and a 
subset of monocytes; thus, a role for reduced monocytes in this phenotype is possible.  In this 
study, we used a genetic approach to systematically examine the contribution of neutrophils and 
other hematopoietic cell populations to G-CSF-induced HSPC mobilization.  We show that G-
CSFR expression on monocytic cells in the bone marrow is sufficient to initiate HSPC 
mobilization by G-CSF.  
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RESULTS 
The mobilization response to G-CSF correlates poorly with the number of wild-type 
neutrophils in the bone marrow.   
To evaluate the importance of neutrophils to G-CSF-induced mobilization, we generated 
a series of bone marrow chimeras by transplanting wild-type and Csf3r-/- bone marrow cells in 
different ratios into lethally-irradiated wild-type mice.  Donor chimerism was assessed in 
peripheral blood leukocytes 6 weeks after transplantation.  As reported previously (76), the 
contribution of Csf3r-/- cells to the B cell lineage was near that expected based on the input ratio 
(Supplemental Figure 2.1).  However, due to the marked competitive advantage of Csf3r+/+ cells 
to the neutrophil lineage, virtually all of the neutrophils in the circulation and bone marrow were 
derived from Csf3r+/+ cells (Figure 2.1D-E and data not shown).  Moreover, the number of 
neutrophils in the blood was similar in all of the chimeras (Supplemental Figure 2.2). 
We next assessed the mobilization response to G-CSF in these chimeras by quantifying 
colony-forming units (CFU-C) in the peripheral blood, bone marrow, and spleen.  We predicted 
that an inverse correlation between Csf3r-/- donor input and HSPC mobilization would be 
observed.  Indeed, the number of CFU-Cs in blood and spleen following treatment with G-CSF 
was highest in the 3-to-1 (wild-type-to-Csf3r-/-) chimeras and progressively decreased with 
increasing Csf3r-/- donor input (Figure 2.1A-C).  Analysis of donor chimerism in mature 
neutrophils (Gr-1hi SSChi) in the bone marrow following G-CSF revealed that the great majority 
of neutrophils were derived from wild-type (Csf3r+/+) cells in all of the chimeras (Figure 2.1D).  
In fact, the correlation between the number of wild-type neutrophils in the bone marrow and 
CFU-C in the blood was poor (Figure 2.1E and 2.1F).   
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G-CSF-induced HSPC mobilization is normal in lymphocyte-deficient mice.  
The contribution of B and T lymphocytes to G-CSF-induced HSPC mobilization is 
controversial. Reca, et al, reported that G-CSF-induced mobilization is impaired in Rag2-/-, 
SCID, and Jh mice (38).   In contrast, Katayama et al reported that Rag1-/- mice and IL-7R-/- mice 
exhibited a normal mobilization response to G-CSF (21).  Herein, we characterized HSPC 
mobilization by G-CSF in two lymphocyte-deficient mouse strains, Rag1-/- and NOD/scid/IL-
2γnull mice.  Rag1-/- mice lack mature B and T cells, and NOD/scid/IL-2γnull mice lack all B, T, 
and NK cells.  Consistent with a previous report (21), HSPC mobilization in Rag1-/- mice was 
comparable to wild-type mice (Figure 2.2A).  In NOD/scid/IL-2γnull mice, the baseline level of 
circulating HSPC was increased and marked mobilization in response to G-CSF was observed 
(Figure 2.2B). These data demonstrate that B, T, and NK cells are not required for G-CSF-
induced mobilization. 
 
Generation of transgenic mice with monocyte-restricted expression of the G-CSFR.   
To evaluate the role of monocytes in G-CSF-induced mobilization, we generated 
transgenic mice in which the CD68 (macrosialin) promoter drives expression of the G-CSFR 
(Figure 2.3A). A previous study established that regulatory elements of the CD68 gene are 
sufficient to direct transgene expression to the monocyte/macrophage lineage (77).  Two 
transgenic founder lines were identified that expressed the green fluorescent protein (GFP) in 
circulating monocytes (data not shown). The transgenic founder mice were crossed with Csf3r-/- 
mice to obtain CD68:mGCSFR;Csf3r-/- mice, hereafter referred to as ‘CD68:G-CSFR mice’.  
Since the phenotype of CD68 transgenic mice derived from the two founder lines was similar, 
the data have been pooled.  Of note, the CD68:G-CSFR mice were generated from B6CDF1 
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donor oocytes and then backcrossed 4 generations onto a C57BL/6 background.  To minimize 
the influence of strain effects on phenotype, littermate controls were used in all studies.   
G-CSFR expression in CD68:G-CSFR mice is predicted to be restricted to cells of the 
monocyte lineage.  To test this prediction, we measured surface expression of the G-CSFR on 
blood leukocytes using a biotinylated G-CSF binding assay (78).  Consistent with previous 
reports, in wild-type and Csf3r+/- mice, expression of the G-CSFR was highest in neutrophils, 
detectable but lower in monocytes, and undetectable in B or T cells (Figure 2.3B & C and data 
not shown). As expected, G-CSFR expression was not detected on any blood leukocytes in 
Csf3r-/- mice. In CD68:G-CSFR mice, the highest expression of the G-CSFR was detected on 
blood monocytes with levels similar to that seen in wild-type or Csf3r+/- mice.  G-CSFR 
expression was barely detectable on neutrophils, and no expression was detected on B or T 
lymphocytes.  Similar data were observed using bone marrow cells (data not shown).  These data 
suggest that hematopoietic expression of the G-CSFR in CD68:G-CSFR mice is mainly limited 
to monocytic cells. 
 
CD68:G-CSFR mice are neutropenic.   
G-CSFR signals on granulocytic precursors are required for normal cell proliferation and 
differentiation (78).  Thus, we predicted that the loss of G-CSFR expression on granulocytic cells 
in CD68:G-CSFR mice would result in neutropenia.  Indeed, CD68:G-CSFR mice display basal 
neutropenia that is similar in magnitude to that seen in Csf3r-/- mice (Table 2.1).  Interestingly, 
CD68:G-CSFR mice had a modest but significant increase in circulating B lymphocytes.  A non-
significant trend to increased B lymphocytes also was seen in the Csf3r-/- mice (78). All other 
measured hematopoietic parameters were normal in the CD68:G-CSFR mice.  
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G-CSF-induced HSPC mobilization is normal in CD68:G-CSFR mice.  
We next evaluated the mobilization response of these mice to G-CSF.  Specifically, we 
measured the number of c-kit+Lin-Sca-1+ (KLS) cells and CFU-C in the blood, bone marrow, 
and spleen after 7 days of G-CSF.  Consistent with previous reports (78), in Csf3r+/- mice, G-
CSF administration resulted in a significant increase in KLS cells and CFU-Cs in the blood and 
spleen (Figure 2.4A & B).  As expected, no mobilization was observed in Csf3r-/- mice.  G-CSF 
treatment of CD68:G-CSFR mice induced HSPC mobilization that was at least as great as that 
observed in control mice.  In fact, a significantly greater number of KLS cells were mobilized to 
the spleen in CD68:G-CSFR mice.   
We have previously shown that G-CSF-induced HSPC mobilization is associated with 
osteoblast suppression and decreased CXCL12 expression in the bone marrow (64). We assessed 
osteoblast suppression by measuring mRNA expression of osteocalcin, a specific marker of 
mature osteoblasts (66).  As reported previously (66), G-CSF treatment resulted in a significant 
decrease in osteocalcin and CXCL12 mRNA expression in the bone marrow of control (Csf3r+/-) 
mice (Figures 2.4C & D).  A similar decrease was observed in CD68:G-CSFR but not Csf3r-/- 
mice following G-CSF administration.  Together, these data suggest that G-CSFR expression in 
monocyte-lineage cells is sufficient to induce HSPC mobilization and osteoblast suppression.  
 
G-CSF treatment of wild-type mice is associated with a loss of monocytic cells in the bone 
marrow.   
To assess the effect of G-CSF on monocytic cells in the bone marrow, we took advantage 
of CX3CR1GFP/+ transgenic mice in which monocytic cells express the green fluorescent protein 
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(GFP) (79).  Based on Gr-1 expression, bone marrow monocytes/macrophages can be divided 
into two distinct subsets: Gr-1high GFP+ inflammatory monocytes/macrophages and Gr-1low GFP+ 
resident monocytes/macrophages (Figure 2.5A) (79). CX3CR1GFP/+ mice were treated with G-
CSF for 5 days and the number of inflammatory and resident monocytes/macrophages in the 
bone marrow determined by flow cytometry.  A recent study suggested that collagenase 
treatment of murine long bones following flushing of bone marrow yields a cell population 
enriched for stromal cells and stromal macrophages (80,81). Thus, in addition to our standard 
bone marrow harvesting, we also analyzed cells in the ‘bone fraction’ obtained after collagenase 
treatment of ‘flushed’ femurs. In each fraction, the number of inflammatory 
monocytes/macrophages was significantly reduced (Figure 2.5B).  A smaller decrease in resident 
monocytes/macrophages in the flushed but not bone fractions also was observed.  We next 
examined the kinetics of monocyte/macrophage loss during G-CSF-induced mobilization (Figure 
2.5C).  Since CX3CR1GFP/+ mice were in limited supply, we performed these experiments using 
wild-type mice, using CD115 to identify monocytic cells. Importantly, the decrease in the 
number of inflammatory and resident monocytes/macrophages in the bone marrow was maximal 
by 3 days of G-CSF treatment, a time point at which osteoblast suppression first becomes evident 
(67). 
  
Macrophages support the growth of osteoblasts in vitro.   
To further evaluate the role of monocytes/macrophages in osteoblast growth and survival, 
we cultured bone marrow stromal cells in the presence or absence of bone marrow macrophages.  
Stromal cells cultured in the presence of macrophages generated many more alkaline 
phosphatase-positive (osteoblast lineage) cells than those cultured in the absence of macrophages 
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(Figure 2.6A).  Moreover, secretion of osteocalcin and CXCL12 into the conditioned media was 
significantly increased in cultures containing macrophages (Figure 2.6B & C).  Of note, no 
alkaline phosphatase colonies or osteocalcin or CXCL12 protein secretion were detected in 
cultures of macrophages alone (data not shown).  These data are consistent with a report by 
Chang and colleagues showing that macrophages induced osteoblast mineralization in vitro (39).  
To determine whether macrophages produce a soluble factor that stimulates osteoblast 
development, we repeated these experiments, this time including transwell cultures in which the 
macrophages were separated from the stromal cells by a semi-permeable membrane (Figure 
2.6D). Mature osteoblast development, as measured by osteocalcin protein secretion into 
conditioned media, was partially induced in the transwell cultures.  Collectively, these data 
suggest that bone marrow macrophages produce factor(s), at least some of which are secreted, 
that support the growth and/or survival of osteoblasts.   
 
DISCUSSION 
The contribution of neutrophils to HSPC mobilization by G-CSF is controversial. 
Neutrophils are a major source of proteases that have been implicated in HSPC mobilization, 
including neutrophil elastase, cathepsin G, and MMP-9 (24,25).  However, the importance of 
these proteases is controversial, as mice lacking these proteases exhibit a normal mobilization 
response to G-CSF (34,35,82). There is strong evidence showing that HSPC mobilization by the 
chemokine interleukin-8 (IL-8) is dependent on neutrophils. Csf3r-/- mice, which are profoundly 
neutropenic, fail to mobilize in response to IL-8 (22).  Moreover, antibody-mediated depletion of 
neutrophils (using anti-CD11a or anti-Gr-1 antibodies) abrogated IL-8-induced HSPC 
mobilization (36,37).  With respect to G-CSF, Pelus and colleagues reported that neutrophil 
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depletion using anti-Gr-1 antibodies attenuated G-CSF-induced HSPC mobilization (34). 
However, Gr-1 is expressed on both neutrophils and a subset of monocytes; thus, a role for 
reduced monocytes in this phenotype is possible.  In the current study, we demonstrate using G-
CSF receptor (G-CSFR) deficient bone marrow chimeras that the mobilization response to G-
CSF is poorly correlated with the number of wild-type neutrophils.  Moreover, CD68:G-CSFR 
mice, which are neutropenic and have barely-detectable expression of G-CSFR on neutrophils, 
exhibit a normal mobilization response to G-CSF. These data, while not excluding a role for 
neutrophils, strongly suggest that G-CSF signals in neutrophils are not sufficient to induce 
normal HSPC mobilization. 
The contribution of lymphocytes to G-CSF-induced HSPC mobilization also is 
controversial. Reca, et al. reported that G-CSF-induced mobilization is impaired in Rag2-/-, 
SCID, and Jh mice, and that this deficit can be reversed through administration of complement-
inducing immunoglobulin (38).  In contrast, Katayama et al reported that Rag1-/- mice and IL-7R-
/- mice exhibited a normal mobilization response to G-CSF (21).  Consistent with the latter 
findings, we observed that Rag1-/- and NOD/scid/IL-2γnull mice exhibit a normal mobilization 
response to G-CSF. The basis for these discrepancies remains unclear.  Though all of these 
mouse lines share deficits in B- and T-lymphopoiesis, there are subtle differences.  For example, 
natural killer activity is normal in Rag1-/- and Rag2-/- mice, but is absent in NOD/scid/IL-2γnull 
mice.  In any case, our data strongly suggest that neither B- and T-lymphocytes nor NK cells are 
required for a normal mobilization response to G-CSF. 
There is accumulating evidence that monocyte lineage cells in the bone marrow 
contribute to osteoblast homeostasis and HSPC trafficking. Chang, et al, demonstrated that 
macrophages are anatomically juxtaposed with endosteal osteoblasts, forming a “canopy” over 
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the osteoblasts at sites of bone formation (39). Moreover, they showed that ablation of monocytic 
cells using the MAFIA transgenic mouse model resulted in a loss of osteoblasts (39). Similarly, 
Winkler et al. recently showed that macrophage ablation using the MAFIA transgenic mouse 
model or through administration of clodronate-loaded liposomes resulted in a loss of osteoblasts 
and HSPC mobilization (40). Finally, Chow, et al. demonstrated in a companion paper in this 
issue of JEM that depletion of monocytic-lineage cells using a variety of methods is sufficient to 
induce mobilization of HSPCs. Together, these data strongly suggest that monocytic cells 
produce trophic factors required for osteoblast maintenance and HSPC retention. Consistent with 
this conclusion, we show that macrophages support osteoblast growth in vitro, at least in part, 
through production of a soluble factor. The identity of these factor(s) is currently unknown. 
In this study, we provide novel evidence that G-CSFR signaling in monocytic cells is 
sufficient to induce HSPC mobilization.  We generated transgenic mice in which expression of 
the G-CSFR is mainly limited to cells of the monocyte lineage and showed that G-CSF-induced 
HSPC mobilization, osteoblast suppression, and decrease in CXCL12 expression are similar to 
control mice.  In the bone marrow, there are at least four distinct monocytic cell populations: 
inflammatory monocytes/macrophages, resident monocytes/macrophages, myeloid dendritic 
cells, and osteoclasts.  Since the CD68 transgene used in our study is expected to direct G-CSFR 
expression in each of these cell populations, all of them are candidates to mediate HSPC 
mobilization.  There is considerable (though conflicting) data on the role of osteoclasts in HSPC 
mobilization.  Kollet and colleagues reported that activation of osteoclasts by injection of RANK 
ligand (RANKL) was associated with moderate HSPC mobilization, and inhibition of 
osteoclasts, either genetically by knocking out PTPε or by injecting mice with calcitonin, blunts 
the mobilization response to G-CSF (42). Of note, osteoclasts produce the protease cathepsin K, 
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which can cleave CXCL12 in vitro (42,43).  On the other hand, other studies indicate that 
osteoclasts may actually inhibit mobilization, as mice that were given pamidronate, an 
osteoclast-inhibiting bisphosphonate, exhibit increased mobilization in response to G-CSF 
(40,44). In contrast to osteoclasts (40,44), we show that inflammatory and resident 
monocytes/macrophages decrease after G-CSF treatment.  Of note, the timing of the decrease in 
these cell populations during G-CSF treatment is similar to that reported for the decrease in 
osteoblasts (67) and precedes HSPC mobilization.  Definitive identification of the monocytic cell 
population that mediates G-CSF-induced HSPC mobilization will require further study.   
In summary, we provide evidence that monocytic cells in the bone marrow are sufficient 
to elicit HSPC mobilization and osteoblast suppression by G-CSF.  These data suggest a model 
in which monocyte lineage cells in the bone marrow produce trophic factors required for the 
maintenance of osteoblasts.  G-CSF-induced suppression of monocytic cells and/or signaling in 
these cells results in decreased production of the putative trophic factors, suppression of 
osteoblast lineage cells (and CXCL12 expression), and ultimately HSPC mobilization.  The 
precise monocytic cell population and factor(s) produced by these cells that regulate osteoblast 
lineage cells are areas of active investigation. 
  
MATERIALS AND METHODS 
Mice. Sex- and age-matched wild-type, Csf3r-/-, and CX3CR1GFP/+ mice on a C57BL/6 
background were maintained under SPF conditions according to methods approved by the 
Washington University Animal Studies Committee (Saint Louis, MO).  The Csf3r-/- mice have 
been previously described (78).  The CX3CR1GFP/+ mice were a generous gift from Dr. Dan 
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Littman (Skirball Institute of Biomolecular Medicine, New York School of Medicine, New York, 
NY).  
 
Generation of Mixed Chimeras. Wild-type (Ly5.1) or Csf3r-/- (Ly5.2) bone marrow cells were 
harvested. A total of 2 million bone marrow cells were mixed at a 3:1, 1:1, 1:3, or 1:9 ratio and 
injected retroorbitally into lethally irradiated wild-type mice (Ly5.1). Recipient mice were 
conditioned with 1000 cGy from a 137Cesium source at a rate of approximately 95 cGy/minute 
before transplantation. Prophylactic antibiotics (trimethoprim-sulfamethoxazole; Alpharma, East 
Bridgewater, NJ) were given during the initial 2 weeks after transplantation. Mice were analyzed 
8 to 10 weeks after transplantation. 
 
Generation of CD68:G-CSFR mouse. To express G-CSF receptor under the control of the 
CD68 promoter, we made use of a variant of the CD68 promoter construct described by Lang, et 
al. (83), in which the 728 bp of sequence 5’ to the ATG and the 83-bp first intron of the human 
CD68 gene were subcloned into the pUR19 backbone. A fragment containing bases 93-2694 of 
the murine G-CSF receptor cDNA, which includes the entire coding region of the murine G-CSF 
receptor, was subcloned into this backbone 3’ of the first CD68 intron. An IRES-GFP cassette 
(derived from pIRES2-eGFP, Clontech) was subcloned into the backbone 3’ of the G-CSF 
receptor fragment. For injection into male nuclei of B6CDF1 zygotes, the construct was digested 
with Dra I and purified according to standard procedures. Offspring derived from the injection 
were screened by PCR for GFP. A sample of peripheral blood was taken from those mice 
positive for GFP by PCR and analyzed for the presence of GFP+ neutrophils and monocytes. 
Transgene-bearing founder mice were mated with C57BL/6 mice with germline deletion of G-
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CSF receptor (Csf3r-/-). Two founder lines produced viable offspring; initial characterization of 
these mice revealed similar mobilization responses to G-CSF, so the data from the two founder 
lines were pooled and are collectively referred to as ‘CD68:G-CSFR’ mice. 
 
Macrophage/osteoblast co-culture. Bone marrow cells were recovered from the femurs of 
wild-type mice by flushing with PBS. The femurs were then infused with PBS containing 50 
mg/ml of type II collagenase (Worthington Biochemical) and incubated at 37°C for 30 minutes. 
The collagenase-treated femurs were flushed again with PBS.  The cells were pooled (containing 
both hematopoietic and stromal cells) and cultured for 7 days in base media (alpha-MEM with 
10% fetal calf serum).  On day 7 of culture, cells were trypsinized and stained with PE-
conjugated anti-mouse CD115 and FITC-conjugated anti-mouse CD45.  CD45+ CD115+ 
(macrophages) and CD45- (stromal cells) were sorted separately using a MoFlo high-speed cell 
sorter (Dako).  CD45- cells were plated at 10,000 cells per well in a 24-well plate in the absence 
or presence of 20,000 CD115+ CD45+ cells.  As a control, 20,000 CD115+ CD45+ were plated 
alone.  In each case, after incubation for 1-2 days in base media, cells were cultured for an 
additional 14 days in base media supplemented with 10 mM beta-glycerophosphate and 50 µg/ml 
ascorbic acid.  Alkaline phosphatase staining was performed on day 14 of culture, per 
manufacturer’s instructions (Vector Laboratories, Burlingame, CA). 
 
G-CSF Mobilization Protocol. Recombinant human G-CSF (Amgen) was diluted in phosphate-
buffered saline with 0.1% low endotoxin BSA (Sigma-Aldrich) and administered at a dose of 
250 µg/kg/day either by daily subcutaneous injection for 5 days or by continuous infusion via 
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subcutaneous osmotic pump for 7 days. Mice were analyzed 3 to 4 hours after the final cytokine 
dose.  
 
CFU-C assays. Blood, bone marrow, and spleen cells were harvested from mice using standard 
techniques and the number of nucleated cells in these tissues was quantified using a Hemavet 
(Drew Scientific) automated cell counter. We plated 10 µL blood, 5 x104 nucleated spleen cells, 
or 2.0 x 104 nucleated bone marrow cells in 2.5 mL methylcellulose media supplemented with a 
cocktail of recombinant cytokines (MethoCult 3434; StemCell Technologies). Cultures were 
plated in duplicate and placed in a humidified chamber with 5% carbon dioxide (CO2) at 37°C. 
After 7 days of culture, the number of colonies per dish was counted. The frequency of colonies 
per femur or spleen was determined based on the number of cells present in the cell suspension 
immediately after harvest. 
 
Real-time quantitative RT-PCR. Femurs were flushed with a total of 0.75 mL TRIzol reagent 
(Invitrogen, Carlsbad, CA). RNA was isolated according to the manufacturer's instructions and 
resuspended in 150 µL RNase/DNase-free water. Real-time reverse transcriptase polymerase 
chain reaction (RT-PCR) was performed using the TaqMan One-step RT-PCR Master Mix 
Reagents Kit (Applied Biosystems, Foster City, CA) on a GeneAmp 5700 Sequence Detection 
System (Applied Biosystems). The reaction mix consisted of 5 µL RNA, 12.5 µL RT-PCR mix, 
200 nM forward primer, 200 nM reverse primer, 280 nM internal probe, and 0.625 µL 
Multiscribe reverse transcriptase and RNase inhibitor in a total reaction volume of 25 µL. 
Reactions were repeated in the absence of reverse transcriptase to confirm that DNA 
contamination was not present. RNA content was normalized to murine β-actin. PCR conditions 
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were 48°C for 30 minutes and 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 
seconds and 60°C for 1 minute. Primers were: CXCL12 forward primer, 5'-
GAGCCAACGTCAAGCATCTG-3'; CXCL12 reverse primer, 5'-
CGGGTCAATGCACACTTGTC-3'; CXCL12 dT-FAM/TAMRA probe, 5'-
TCCAAACTGTGCCCTTCAGATTGTTGC-3'; β-actin forward primer, 5'-
ACCAACTGGGACGATATGGAGAAGA-3'; β-actin reverse primer, 5'-
TACGACCAGAGGCATACAGGGACAA-3'; β-actin dT-FAM/TAMRA probe, 5'-
AGCCATGTACGTAGCCATCCAGGCTG-3'; osteocalcin forward primer, 5'-
TCTCTCTGCTCACTCTGCTGGCC-3'; osteocalcin reverse primer, 5'-
TTTGTCAGACTCAGGGCCGC-3'; and osteocalcin dT-FAM/TAMRA probe, 5'-
TGCGCTCTGTCTCTCTGACCTCACAGATGCCA-3'. 
 
Flow Cytometry. Red blood cells in peripheral blood and bone marrow mononuclear cell 
preparations were lysed in Tris-buffered ammonium chloride (pH 7.2) buffer and incubated with 
the indicated antibody at 4°C for 1 hr in PBS containing 0.1% sodium azide, 1 mM EDTA, and 
0.2% (w/v) BSA to block nonspecific binding. The following directly-conjugated monoclonal 
antibodies were used:  allophycocyanin‐eFluor 780-conjugated rat anti‐mouse Gr‐1 (RB6-8C5, 
IgG2b; eBioscience); allophycocyanin-conjugated rat anti-mouse CD115 (AFS98, IgG2a; 
eBioscience); fluorescein isothiocyanate (FITC)-conjugated rat anti–mouse Gr-1 (RB6-8C5, 
IgG2b; eBioscience); allophycocyanin-conjugated rat anti-mouse CD3e (17A2, IgG2b; 
eBioscience); and allophycocyanin‐eFluor 780-conjugated rat anti‐mouse B220 (RA3-6B2, 
IgG2a, eBioscience). For KLS analysis, we used the following antibodies: phycoerythrin (PE)-
conjugated rat anti-mouse Gr-1 (RB6-8C5, IgG2b; eBioscience); PE-conjugated rat anti‐mouse 
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B220 (RA3-6B2, IgG2a, eBioscience); PE-conjugated Armenian hamster anti-mouse CD3e 
(145-2C11, IgG, eBioscience); PE-conjugated rat anti-mouse Ter-119 (TER-119, IgG2b, 
eBioscience); rat anti-mouse Sca-1 (D7, IgG2a, eBioscience); and rat anti-mouse c-kit (2B8, 
IgG2b, eBioscience). To assess surface G-CSFR expression, G-CSF was biotinylated using 
NHS-LC-biotin (Pierce) as previously described (84). Peripheral blood mononuclear cells were 
incubated at 4°C for 1 h with biotinylated G-CSF (25 ng per 106 cells) in the presence or absence 
of a 100-fold molar excess of nonlabeled G-CSF, followed by incubation with PE-conjugated 
streptavidin. All cells were analyzed on a FACScan flow cytometer. 
 In some cases, the ‘bone’ fraction of the bone marrow was analyzed by flow cytometry.  
In brief, bone marrow was extracted from femurs either by flushing with PBS or by 
centrifugation at 3,300 x g for 1 minute at room temperature; the pellet was set aside for analysis 
as the ‘flushed’ fraction. The ‘flushed’ femurs were then pulverized with a mortar and pestle, and 
the bone chips were incubated with PBS containing 2 mg/mL type II collagenase (Worthington 
Biochemical) at 37°C for 60 minutes with agitation. After allowing the bone chips to settle by 
gravity, the cell suspension was harvested and analyzed.  
 
CXCL12 and osteocalcin ELISAs. For enzyme-linked immunosorbent assays (ELISAs), 96-
well plates were coated with 100 µL CXCL12 capture antibody (2 µg/mL) diluted in PBS and 
incubated overnight at room temperature. After incubation for 1 hour at room temperature with 
300 µL blocking solution (1% BSA, 5% sucrose, and 0.05% NaN3), 100 µL sample was added to 
each well and incubated for 2 hours at room temperature. After washing, 100 µL polyclonal 
biotinylated anti–human CXCL12 (250 ng/mL) in ELISA diluent (0.1% BSA, 0.05% Tween 20 
in Tris [tris(hydroxymethyl-)aminomethane)]–buffered saline at pH 7.3) was added to each well 
	  	   27 
and incubated at room temperature for 2 hours. The reaction was developed by successive 
incubations with 1 µg/mL horseradish peroxidase streptavidin, substrate solution, and 50 µL 2N 
H2SO4 to stop the reaction. A microplate reader set at 450 nm was used to determine optical 
density with readings at 570 nm subtracted from the results. Recombinant human CXCL12α was 
used to generate a standard curve.  CXCL12 ELISA reagents were purchased from R&D 
Systems (Minneapolis, MN). Osteocalcin ELISA was performed using a kit according to the 
manufacturer’s instructions (Human Osteocalcin Instant ELISA, Catalog No. BMS2020INST, 
BenderMed Systems, Vienna, Austria). 
 
Statistics. Significance was determined using Prism software (GraphPad). Statistical 
significance of differences was calculated using 2-tailed Student’s t tests (assuming equal 
variance) or, where indicated, 1- or 2-way ANOVA with Bonferroni’s or Dunnett’s post-testing. 
P values less than 0.05 were considered significant. All data are presented as mean ± SEM 
except as noted. 
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TABLES AND FIGURES 
 
Table 2.1: Peripheral Blood Counts 
Parameter Csf3r+/- Csf3r-/- CD68:G-CSFR 
Csf3r+/-  
vs.  
Csf3r-/-† 
Csf3r+/- 
vs.  
CD68:G-
CSFR† 
Hemoglobin (g/dL) 13.80 ± 1.01 15.57 ± 1.06 18.00 ± 2.83 ns ns 
Platelets (K/µL) 820 ± 147 701 ± 90 678 ± 188 ns ns 
Leukocytes (K/µL) 8.76 ± 1.82 8.51 ± 4.10 9.82 ± 2.56 ns ns 
Neutrophils (K/µL) 1.38 ± 0.62 0.16 ± 0.03 0.24 ± 0.05 p < 0.001 p < 0.001 
Monocytes (K/µL) 0.24 ± 0.12 0.12 ± 0.08 0.25 ± 0.06 ns ns 
B cells (K/µL) 2.75 ± 0.57 3.53 ± 1.52 4.92 ± 1.53 ns p < 0.05 
T cells (K/µL) 1.95 ± 0.75 2.23 ± 0.82 1.78 ± 0.42 ns ns 
      
Values represent mean ± standard deviation for 2-5 mice per genotype and is pooled from three 
independent experiments. 
†Comparisons made using a one-way ANOVA with Bonferroni's post test corrected for multiple 
comparisons 
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Figure 2.1 
 
Neutrophil number in the bone marrow correlates poorly with G-CSF-induced HSPC 
mobilization. Wild-type and Csf3r-/- bone marrow cells were mixed at the indicated ratios and 
transplanted into irradiated recipients.  Six weeks later, the mixed bone marrow chimeras were 
treated with G-CSF (250 µg/kg/day G-CSF for 7 days), and the number of CFU-C in the (A) 
peripheral blood, (B) spleen, or (C) bone marrow was measured.  As a control, a cohort of mixed 
chimeras was analyzed without G-CSF treatment (UnRx); since similar results were obtained 
with each type of chimera, the untreated data were pooled.  The percentage of neutrophils in the 
bone marrow derived from wild-type cells (D) and the absolute number of wild-type neutrophils 
per femur (E) were determined after 7 days of G-CSF administration.  (F) The number of CFU-C 
in the blood versus the number of wild-type neutrophils in bone marrow.  The Pearson r2 value is 
shown.  Data represent the mean ± SEM of 6-9 mice and is pooled from two independent 
transplantation experiments.  *P < 0.05 compared with untreated chimeras; +P < 0.05 compared 
with 3-to-1 chimeras.   
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Figure 2.2 
 
G-CSF-induced HSPC mobilization is normal in Rag1-/- and NOD/scid/IL-2γnull mice. Wild-
type, Rag1-/- (A), or NOD/scid/IL-2γnull mice (B) were treated with G-CSF (250 µg/kg/day for 5 
days) or left untreated.  The number of CFU-C in the blood, bone marrow, and spleen was 
measured after 5 days of G-CSF. Data represent the mean ± SEM of 4-5 mice per genotype per 
treatment group and is pooled from four independent experiments.  *P < 0.01; **P <0.001. 
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Figure 2.3 
 
G-CSFR expression is mainly restricted to monocytic cells in CD68:G-CSFR mice.  (A) 
Schematic of the CD68:G-CSFR transgene.  IRES: internal ribosomal entry sequence; GFP: 
green fluorescent protein.  (B) Representative histograms showing biotinylated G-CSF binding in 
the absence (solid line) or presence (dashed line) of a 100-fold molar excess of unlabeled G-CSF 
in the indicated blood leukocyte population.  G-CSFR surface expression is proportional to the 
difference in median fluorescence intensity (∆MFI) between the two curves.  (C) The average 
∆MFI in the indicated blood leukocyte population is shown.  Data represent the mean ± SEM of 
4-5 mice of per genotype and is pooled from four independent experiments. 
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Figure 2.4 
 
G-CSF-induced HSPC mobilization is normal in CD68:G-CSFR mice.  Mice of the indicated 
genotype were treated with G-CSF for 7 days or left untreated.  The number of KLS (A) or CFU-
C (B) in the blood, bone marrow, and spleen on day 7 is shown.  The mRNA expression in the 
bone marrow on day 7 of osteocalcin (C) or CXCL12 (D) relative to β-actin is shown.  Data 
represent the mean ± SEM of 3-5 mice per genotype per treatment group and is pooled from 
three independent experiments. *P < 0.05 compared with untreated mice of the same genotype. 
**P < 0.01 compared with untreated mice of the same genotype. †P < 0.05 and ‡P = 0.07 
compared with G-CSF-treated Csf3r+/- mice.   
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Figure 2.5 
 
G-CSF treatment leads to a loss of monocytic cells from the bone marrow. CX3CR1GFP/+ 
mice were treated with PBS or G-CSF for 5-7 days and the flush and bone fractions harvested as 
described in Methods.  (A) Representative dot-plot showing the gating strategy used to identify 
inflammatory (Gr-1high GFP+) and resident monocytes/macrophages (Gr-1low GFP+).  (B) The 
absolute number of inflammatory and resident monocytes/macrophages in the flushed and bone 
fractions are shown.  Data represent the mean ± SEM of four mice per cohort pooled from two 
independent experiments.  *P < 0.05, **P < 0.005, and  ***P < 0.001.  (C) The percentage of 
inflammatory and resident monocytes in the flush fraction of bone marrow was determined at the 
indicated time points.  In these experiments, wild-type mice rather than CX3CR1GFP/+ mice were 
employed, and CD115 was used to identify monocytic cells. Data represent mean ± SEM of 2-6 
mice per cohort pooled from 4 independent experiments. **P < 0.005 compared to untreated 
mice as determined by one-way ANOVA with Dunnett's post-test to correct for multiple 
comparisons.  
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Figure 2.6	  
 
Macrophages support the growth of mature osteoblasts in vitro. Unfractionated bone marrow 
cells from wild-type mice were cultured for 10 days, and then sorted by flow cytometry into 
stromal (CD45- Ter119-) and macrophage (CD45+ CD115+) cell populations.  Stromal cells were 
cultured for an additional 14 days in the absence (No Mø) or presence (Mø) of an equal number 
of macrophages.  Ascorbic acid and calcium were included in all cultures to stimulate mature 
osteoblast development.  (A) Representative photomicrographs of cultures on day 14 that were 
stained for alkaline phosphatase.  (B) Osteocalcin protein concentration in conditioned media 
was measured by ELISA at the indicated time points.  CXCL12 protein (C) and Osteocalcin (D) 
concentrations in conditioned media were measured by ELISA on day 14 of culture.  Where 
indicated, the macrophages were separated from the stromal cells by a semi-permeable 
membrane (transwell).  Data represent the mean ± SEM of 3 independent experiments. *P < 0.05, 
**P < 0.005, and ***P < 0.001.  
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Supplemental Figure 2.1 
 
B lymphocyte chimerism in mixed Csf3r-/- chimeras.  Mixed bone marrow chimeras were 
established by transplanting the indicated ratio of wild type-to-Csf3r-/- bone marrow cells into 
lethally irradiated recipients.   Donor chimerism of peripheral blood B lymphocytes was assessed 
by flow cytometry 5-6 weeks after transplantation.  Data represent the mean ± SEM of 6-9 mice 
and is pooled from two independent experiments.   
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Supplemental Figure 2.2 
 
Absolute number of neutrophils in mixed Csf3r-/- chimeras.  Shown is the absolute number of 
neutrophils in the peripheral blood prior to G-CSF treatment.  Greater than 95% of all 
neutrophils were derived from wild-type cells in each case (data not shown).  Data represent the 
mean ± SEM of 6-9 mice and is pooled from two independent experiments.   
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CHAPTER 3 
OSTEOCLASTS ARE NOT REQUIRED FOR 
G-CSF-INDUCED HSPC MOBILIZATION 	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INTRODUCTION 
In the healthy adult, a majority of hematopoietic stem cells reside within the bone 
marrow. In response to various forms of physiologic stress, such as infection or hemorrhage, 
these cells are released into the peripheral circulation, a process termed ‘hematopoietic stem cell 
mobilization.’ In the late 1980s, it was observed that large numbers of hematopoietic stem and 
progenitor cells could be mobilized through administration of hematopoietic growth factors such 
as granulocyte-colony stimulating factor (G-CSF) (1,2). This observation proved to be of great 
clinical utility, as these mobilized HSCs could be harvested from the peripheral blood and used 
for hematopoietic stem cell transplantation (HSCT); in fact, several studies have demonstrated 
that use of mobilized peripheral blood stem cells in HSCT is associated with more rapid 
engraftment and a lower incidence of graft-versus-host disease (9-13) . Currently, G-CSF is the 
most commonly used and most effective mobilizing agent. Nearly 20% of stem cell donors, 
however, fail to mobilize enough hematopoietic stem cells for successful HSCT using standard 
mobilization regimens (18). Efficient development of novel mobilizing agents requires a detailed 
understanding of the mechanisms that regulate stem cell trafficking, 
We recently reported that G-CSF acts on monocytic cells to elicit HSPC mobilization and 
that treatment with G-CSF leads to loss of certain monocyte subsets from the bone marrow (85). 
Similarly, two other groups demonstrated that ablation of monocytic cells is sufficient to cause 
mobilization of HSPCs (40,41). Together, these data suggest that monocytic cells play an 
important role in the retention of HSPCs within the bone marrow and that G-CSF may elicit 
HSPC mobilization, at least in part, through the suppression of monocytic cells. We sought to 
extend and refine these findings by evaluating the importance of certain monocytic subsets both 
to the retention of HSPCs within the marrow and the mobilization response to G-CSF.  
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Within the bone marrow monocytic lineage, there are three major cell types: 1) 
osteoclasts; 2) myeloid dendritic cells; and 3) bone marrow macrophages. In this study, we 
evaluated the role of osteoclasts and myeloid dendritic cells in HSPC retention within the bone 
marrow as well as in the mobilization response to G-CSF using a pair of ablation models. The 
role of bone marrow macrophages has been difficult to elucidate, largely owing to the lack of 
tools to selectively ablate them. Use of clodronate-loaded liposomes (40,41) or Mafia transgenic 
mice (40) have been used in the past, but these agents appear to target multiple monocytic 
populations, and, at least in the case of the Mafia mice, the ablation paradigm results in a 
systemic inflammatory response, making it impossible to separate the effects of the cytokine 
storm from the effects of the G-CSF (Daniel C. Link, unpublished data). A recent study by 
Chow, et al. demonstrated ablation of CD169+ macrophages without a corresponding loss of 
inflammatory or resident monocytes using a diphtheria-toxin inducible system, reporting that 
ablation of these CD169+ macrophages was sufficient to elicit mobilization of HSPCs, 
suggesting a key role for these cells in HSPC retention within the marrow (41). However, our 
analysis of CD169 expression in bone marrow suggests that other populations such as 
granulocytic precursors express high levels of CD169, thereby confounding the interpretation of 
the data. A definitive assessment of the role of these macrophages will require development of 
more sophisticated models. 
In recent years, the role of osteoclasts in G-CSF-induced mobilization has received 
considerable attention, but the absence of a model system where osteoclasts can be transiently 
ablated – thus avoiding the complications of assaying hematologic parameters in the presence of 
severe osteopetrosis – has made drawing definitive conclusions on their role difficult. In this 
study, we used osteoprotegerin-Fc, a stabilized form of the RANK ligand decoy receptor 
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osteoprotegerin, to transiently but completely ablate osteoclasts and measured the effect both on 
HSPC retention within the marrow as well as in response to G-CSF. We report herein that loss of 
osteoclasts does not lead to spontaneous mobilization of HSPCs, nor does it alter the 
mobilization response to G-CSF. 
Along with bone marrow macrophages and osteoclasts, monocytic cells give rise to a 
subset of antigen-presenting cells referred to as myeloid (or bone-marrow resident) dendritic 
cells. They can be identified immunophenotypically by their high expression of both CD11c and 
MHC Class II. They represent approximately 0.22% of bone marrow leukocytes and are 
concentrated in perivascular spaces, where they are believed to participate in 
immunosurveillance (86). They are also believed to have a role in promoting survival of 
recirculating B cells, as their ablation results in a profound loss of recirculating B cells (86). In 
contrast to osteoclasts, however, very little is known about their role in regulation of HSPC 
trafficking or G-CSF-induced mobilization. Using a diphtheria toxin-based approach to 
transiently ablate myeloid dendritic cells, we report that their loss is associated with an 
augmented response to G-CSF and that ablation of myeloid dendritic cells leads to a partial 
suppression of osteoblasts, suggesting a previously-unidentified role for myeloid dendritic cells 
in regulation of stromal cell populations. 
MATERIALS AND METHODS 
Mice. Wild-type mice on a C57BL/6 background were maintained under SPF conditions 
according to methods approved by the Washington University Animal Studies Committee (Saint 
Louis, MO). The CD11c-DTR expressing mice were obtained from Jackson Labs.  
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Generation of Chimeras.  Bone marrow cells from mice carrying the CD11c-DTR transgene or 
their non-transgenic littermates (both Ly5.2) were harvested. A total of 2 million bone marrow 
cells were injected retroorbitally into lethally irradiated wild-type mice (Ly5.1). Recipient mice 
were conditioned with 1000 cGy from a 137Cesium source at a rate of approximately 95 
cGy/minute before transplantation. Prophylactic antibiotics (trimethoprim-sulfamethoxazole; 
Alpharma, East Bridgewater, NJ) were given during the initial 2 weeks after transplantation. 
Mice were analyzed 8 to 10 weeks after transplantation. 
 
G-CSF Mobilization Protocol. Recombinant human G-CSF (Amgen) was diluted in phosphate-
buffered saline with 0.1% low endotoxin BSA (Sigma-Aldrich) and administered at a dose of 
250 µg/kg/day either by daily subcutaneous injection for either 5 or 7 days. Mice were analyzed 
12-15 hours after the final cytokine dose.  
 
CFU-C assays. Blood, bone marrow, and spleen cells were harvested from mice using standard 
techniques and the number of nucleated cells in these tissues was quantified using a Hemavet 
(Drew Scientific) automated cell counter. We plated 10 µL blood, 5 x104 nucleated spleen cells, 
or 2.0 x 104 nucleated bone marrow cells in 2.5 mL methylcellulose media supplemented with a 
cocktail of recombinant cytokines (MethoCult 3434; StemCell Technologies). Cultures were 
plated in duplicate and placed in a humidified chamber with 5% carbon dioxide (CO2) at 37°C. 
After 7 days of culture, the number of colonies per dish was counted. The frequency of colonies 
per femur or spleen was determined based on the number of cells present in the cell suspension 
immediately after harvest. 
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Real-time quantitative RT-PCR. Femurs were flushed with a total of 0.75 mL TRIzol reagent 
(Invitrogen, Carlsbad, CA). RNA was isolated according to the manufacturer's instructions and 
resuspended in 50 µL RNase/DNase-free water. Real-time reverse transcriptase polymerase 
chain reaction (RT-PCR) was performed using the TaqMan One-step RT-PCR Master Mix 
Reagents Kit (Applied Biosystems, Foster City, CA) on a GeneAmp 7300 Sequence Detection 
System (Applied Biosystems). The reaction mix consisted of 5 µL RNA, 10 µL RT-PCR mix, 
200 nM forward primer, 200 nM reverse primer, 280 nM internal probe, and 0.5 µL Multiscribe 
reverse transcriptase and RNase inhibitor in a total reaction volume of 20 µL. Reactions were 
repeated in the absence of reverse transcriptase to confirm that DNA contamination was not 
present. RNA content was normalized to murine β-actin in a multiplex PCR reaction. PCR 
conditions were 48°C for 15 minutes and 95°C for 10 minutes, followed by 40 cycles of 95°C for 
15 seconds and 60°C for 1 minute. Primers were: CXCL12 forward primer, 5'-
GAGCCAACGTCAAGCATCTG-3'; CXCL12 reverse primer, 5'-
CGGGTCAATGCACACTTGTC-3'; CXCL12 dT-FAM/TAMRA probe, 5'-
TCCAAACTGTGCCCTTCAGATTGTTGC-3'; osteocalcin forward primer, 5'-
TCTCTCTGCTCACTCTGCTGGCC-3'; osteocalcin reverse primer, 5'-
TTTGTCAGACTCAGGGCCGC-3'; and osteocalcin dT-FAM/TAMRA probe, 5'-
TGCGCTCTGTCTCTCTGACCTCACAGATGCCA-3'. Mixtures of primers and FAM-
conjugated probes for cathepsin K, tartrate-resistant acid phosphatase and a VIC-conjugated 
probe for beta-actin were obtained from Applied Biosystems Gene Expression Assay repository. 
 
Flow Cytometry. Red blood cells in peripheral blood and bone marrow mononuclear cell 
preparations were lysed in Tris-buffered ammonium chloride (pH 7.2) buffer and incubated with 
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the indicated antibody at 4°C for 1 hr in PBS containing 0.1% sodium azide, 1 mM EDTA, and 
0.2% (w/v) BSA to block nonspecific binding. The following directly-conjugated monoclonal 
antibodies were used:  allophycocyanin‐eFluor 780-conjugated rat anti‐mouse Gr‐1 (RB6-8C5, 
IgG2b; eBioscience); allophycocyanin-conjugated rat anti-mouse CD115 (AFS98, IgG2a; 
eBioscience); fluorescein isothiocyanate (FITC)-conjugated rat anti–mouse Gr-1 (RB6-8C5, 
IgG2b; eBioscience); allophycocyanin-conjugated rat anti-mouse CD3e (17A2, IgG2b; 
eBioscience); and allophycocyanin‐eFluor 780-conjugated rat anti‐mouse B220 (RA3-6B2, 
IgG2a, eBioscience). For KLS analysis, we used the following antibodies: phycoerythrin (PE)-
conjugated rat anti-mouse Gr-1 (RB6-8C5, IgG2b; eBioscience); PE-conjugated rat anti‐mouse 
B220 (RA3-6B2, IgG2a, eBioscience); PE-conjugated Armenian hamster anti-mouse CD3e 
(145-2C11, IgG, eBioscience); PE-conjugated rat anti-mouse Ter-119 (TER-119, IgG2b, 
eBioscience); rat anti-mouse Sca-1 (D7, IgG2a, eBioscience); and rat anti-mouse c-kit (2B8, 
IgG2b, eBioscience). For identification of myeloid dendritic cells, we used a PE/Cy7-conjugated 
anti-mouse CD11c antibody and a PerCP/Cy5.5-conjugated anti-mouse MHC Class II antibody 
(both available from Biolegend). All cells were analyzed either on FACScan or Gallios flow 
cytometers. 
 
Statistics. Significance was determined using Prism software (GraphPad). Statistical 
significance of differences was calculated using 2-tailed Student’s t tests (assuming equal 
variance) or, where indicated, 1- or 2-way ANOVA with Bonferroni’s or Dunnett’s post-testing. 
P values less than 0.05 were considered significant. All data are presented as mean ± SEM 
except as noted. 
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Chemicals. All chemicals were obtained form Sigma unless otherwise noted. Diphtheria toxin 
was reconstituted to a final concentration of 1 µg/µL in PBS + 0.1% bovine serum albumin and 
was given via intraperitoneal injection at a final dose of 4 ng diphtheria toxin per gram body 
weight according to the experimental paradigm. Osteoprotegerin-Fc was a generous gift of 
Amgen (Thousand Oaks, CA). It was diluted to a final concentration of 1 mg/mL with PBS + 
0.1% BSA and administered as a single 100 µg dose via subcutaneous injection. 
 
Immunohistochemistry. Femurs from mice were fixed in 10% neutral buffered formalin 
overnight. Excess fixative was rinsed off and bones were decalcified in 10% EDTA for two 
weeks before being rehydrated and embedded in paraffin. 7-µm sections were prepared from 
each of the blocks and stained for tartrate-resistant acid phosphatase (TRAP) using standard 
protocols. Sections were counterstained with hematoxylin. 
RESULTS 
Osteoclasts are not required for retention of HSPCs in the bone marrow. 
To evaluate the importance of osteoclasts in the retention of HSPCs within the marrow, 
we measured HSPC frequency in the peripheral blood, bone marrow, and spleen following 
osteoclast ablation with osteoprotegrin-Fc (OPG-Fc), a chimera of recombinant human 
osteoprotegerin (OPG) and the Fc immunoglobulin domain. Murine osteoclast formation is 
dependent on RANKL/RANK signaling, and mice with targeted deletion of either RANK or 
RANKL do not form mature osteoclasts (87). In vivo, RANKL is secreted primarily by mature 
osteoblasts, where it binds to RANK on osteoclast progenitors to promote formation of mature 
osteoclasts. Osteoblasts also produce osteoprotegerin (OPG), which serves as a decoy receptor 
for RANK ligand. The relative expression of RANKL and OPG is a key determinant of whether 
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osteoclast formation is supported or inhibited (88). Administration of OPG-Fc reduces the ratio 
of RANKL to OPG, causing a complete, but transient ablation of osteoclasts in mice (89). 
In our experiments, mice were given a single dose of 100 µg OPG-Fc; at various times 
after receiving OPG-Fc, they were sacrificed and samples of peripheral blood, bone marrow, and 
spleen were taken. To estimate the number of stem cells, the frequency of c-kit+ Sca-1+ Lin- 
(KLS) cells was measured by flow cytometry. To estimate the number of progenitor cells, the 
frequency of colony-forming units (CFU-Cs) was measured. According to the published 
literature on the pharmacokinetics of OPG-Fc, the treatment regimen used in this experiment 
should result in complete osteoclast ablation within four days after OPG-Fc administration, and 
the ablation should last for eight additional days (89). To determine whether osteoclast ablation 
had occurred in our experimental paradigm, we stained sections from mice seven days after 
OPG-Fc administration for tartrate-resistant acid phosphatase (TRAP) activity, a marker of 
mature osteoclasts. Indeed, compared to untreated mice, OPG-Fc-treated mice displayed nearly a 
complete loss of TRAP-positive cells in the bone marrow (Supplemental Figure 3.1).  
We predicted that if osteoclasts promoted retention of HSPCs within the marrow, the loss 
of osteoclasts should result in an increase in the frequency of hematopoietic stem and progenitor 
cells in the peripheral blood and/or the spleen. However, we did not detect any significant 
increase in the frequency of hematopoietic stem or progenitor cells in either the peripheral blood 
or spleen up to nine days after OPG-Fc administration (Figure 3.1A, B). These data suggest that 
osteoclasts are not required for retention of HSPCs within the bone marrow.  
Osteoclasts are not required for G-CSF-induced mobilization. 
The role of osteoclasts in G-CSF-induced mobilization is controversial. Several studies 
have suggested that osteoclast function is positively correlated with HSPC mobilization.  Kollet, 
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et al. reported that administration of soluble RANK ligand, which activates osteoclasts, induces a 
mild mobilization response, suggesting that osteoclast activation may promote mobilization (42), 
a phenomenon that has also been observed by an independent group (90). Kollet, et al. also 
reported that physiologic stress, such as hemorrhage or lipopolysaccharide (LPS) administration, 
leads to osteoclast activation that is coincident with mobilization. Similarly, female mice lacking 
PTP-epsillon, which have a mild osteoclast defect, have a diminished mobilization response to 
G-CSF.  More recently, the same group reported that mice deficient in CD45, which have 
reduced osteoclast maturation and activity, have a reduced mobilization response to G-CSF (91).  
In contrast, several other groups have suggested that osteoclast activity is negatively 
correlated with mobilization. Takamatsu, et al. reported that pamidronate, one of the first-
generation bisphosphonates, augments the mobilization response to G-CSF, suggesting that 
osteoclasts negatively regulate the mobilization response to G-CSF (44). More recently, Winkler, 
et al. reported that zoledronate, one of the newer-generation bisphosphonates reported to induce 
osteoclast apoptosis in vivo (92), also augments the mobilization response to G-CSF (40). Using 
a similar dosing regimen as Winkler, et al., we also observed that zoledronate augmented the 
mobilization response to G-CSF; however, administration of zoledronate alone was not 
associated with a significant reduction in numbers of mature osteoclasts, as measured by TRAP 
staining (Supplemental Figure 3.2), making it difficult to evaluate the role of osteoclasts in G-
CSF-induced mobilization based on these data alone.   
We sought to definitively determine whether osteoclasts are required for G-CSF-induced 
mobilization of HSPCs using the OPG-Fc ablation model described above. Wild-type mice were 
pre-treated with a single dose of 100 µg OPG-Fc or left untreated; four days later they started a 
five-day course of G-CSF. The frequency of HSPCs in the peripheral blood, bone marrow, and 
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spleen was measured before and after the G-CSF treatment regimen. We predicted that if 
osteoclasts were required for G-CSF-induced mobilization, mice pre-treated with OPG-Fc should 
exhibit a blunted mobilization response to G-CSF. In fact, mice pre-treated with OPG-Fc 
demonstrated the same mobilization response to G-CSF as mice that had not been pre-treated, as 
measured by the frequency of KLS cells and CFU-Cs in the peripheral blood and spleen (Figure 
3.2). These data suggest that osteoclasts are not required for G-CSF-induced mobilization of 
HSPCs.   
Myeloid dendritic cell ablation augments G-CSF-induced HSPC mobilization. 
To determine whether myeloid dendritic cells were required for G-CSF-induced 
mobilization of HSPCs, we measured the mobilization response to G-CSF after myeloid 
dendritic cell ablation in CD11c-DTR chimeric mice (93). Administration of diphtheria toxin to 
these mice elicits a transient ablation of CD11c-expressing cells, including myeloid dendritic 
cells. A single dose of diphtheria toxin ablates its target cells within eight hours, and the ablation 
lasts for approximately two days. Sustained ablation can be achieved with multiple doses of 
diphtheria toxin, although this may cause systemic toxicity. However, if marrow from CD11c-
DTR mice is transplanted into lethally-irradiated wild-type mice, sustained ablation of dendritic 
cells can be achieved through repeated administrations of diphtheria toxin without significant 
systemic toxicity (94). In contrast to the rapid kinetics associated with cytokine-induced HSPC 
mobilization, G-CSF-induced mobilization occurs over the course of days, with an increase in 
peripheral HSPC frequency first evident at 3-4 days after beginning treatment. In order to be able 
to accurately evaluate the role of myeloid dendritic cells in G-CSF-induced mobilization, 
therefore, it was necessary to be able to ablate dendritic cells for a period of at least three days. 
To accomplish this, lethally-irradiated wild-type mice received marrow either from mice 
	  	   48 
carrying the CD11c-DTR transgene or their non-transgenic littermates. Once hematopoietic 
reconstitution had occurred, all of the mice received two doses of diphtheria toxin, spaced 48 
hours apart. Twenty-four hours after the first dose of diphtheria toxin was administered, half of 
the mice in each group started a seven-day course of 250 µg/kg/day G-CSF. At the end of the G-
CSF treatment regimen, the mobilization response to G-CSF was evaluated by measuring the 
frequency of KLS cells and CFU-Cs in the peripheral blood, bone marrow, and spleen.  A 
diagram depicting the experimental paradigm is shown in Figure 3.3A. We predicted that if 
myeloid dendritic cells were required for G-CSF-induced mobilization, the CD11c-DTR 
chimeras would not mobilize in response to G-CSF. Surprisingly, we observed the opposite 
phenomenon, wherein the CD11c-DTR chimeras mobilize more HSPCs to the periphery in 
response to G-CSF than the non-transgenic chimeras (Figure 3.3B, C). This increase was seen 
with both KLS cell and CFU-C frequency, indicating that it is occurring at both the level of the 
hematopoietic stem cells and their more committed progenitors. We wondered if the increased 
mobilization could be the result of generalized inflammation that occurred as a result of dendritic 
cell ablation or diphtheria toxin administration. We did not, however, observe significant 
numbers of HSPCs in the periphery of non-transgenic chimeras that received only diphtheria 
toxin, making it unlikely that the diphtheria toxin itself elicited mobilization. Furthermore, we 
did not observe significant numbers of HSPCs in the periphery of CD11c-DTR chimeras that 
received only diphtheria toxin, indicating that the ablation of myeloid dendritic cells did not 
result in a massive systemic inflammatory response. Consistent with this, all of the mice in this 
experiment appeared well at the time of sacrifice, exhibiting normal grooming and feeding 
behavior. Thus, it is unlikely that the increased response to G-CSF observed in the CD11c-DTR 
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chimeras is solely the result of a systemic inflammatory response, but the basis for this 
observation remains unclear. 
Myeloid dendritic cell ablation augments G-CSF-induced leukocytosis and suppression of 
mature osteoblasts, but not G-CSF-induced suppression of CXCL12 production. 
In addition to mobilizing HSPCs from the bone marrow into the periphery, G-CSF 
treatment is associated with a number of other hematopoietic and stromal changes, including 
peripheral leukocytosis (primarily neutrophilia) (95-97), suppression of mature osteoblasts 
(21,64,66,67), and suppression of bone marrow CXCL12 production (28,29,95).  Given that 
myeloid dendritic cell ablation augmented the HSPC mobilization response to G-CSF, we 
wondered whether any other aspects of the response to G-CSF were similarly affected. As shown 
in Figure 3.4A, CD11c-DTR chimeras treated with both diphtheria toxin and G-CSF have a 
much higher peripheral blood leukocyte concentration than similarly-treated non-transgenic 
counterparts. A peripheral blood smear performed on blood samples taken from these CD11c-
DTR chimeras revealed that the increased leukocyte count in the peripheral blood could be 
attributed to increased neutrophil counts; no blasts were observed in the sample (data not 
shown), consistent with an augmented response to G-CSF.  Using RNA isolated from tibial 
flushes, we measured expression of CXCL12 and osteocalcin – a marker of mature osteoblasts – 
in the bone marrow. We observed that G-CSF-induced suppression of osteocalcin expression 
was greater in CD11c-DTR chimeras than in non-transgenic chimeras (Figure 3.4B). In contrast, 
the degree to which G-CSF-induced suppression of CXCL12 was not significantly different 
between CD11c-DTR chimeras and non-transgenic chimeras.  These data raise the possibility 
that the G-CSF’s effects on total CXCL12 production occur through mechanisms distinct from 
that which causes osteoblast suppression, the latter involving myeloid dendritic cells. 
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Analysis of osteocalcin expression in the various groups also suggested ablation of 
myeloid dendritic cells was itself sufficient to reduce osteoblast numbers (Figure 3.4B, 
comparing DT-only treated non-transgenic chimeras with DT-only treated CD11c-DTR 
chimeras) without significantly altering total bone marrow CXCL12 expression (Figure 3.4C, 
comparing the same two groups). These data are consistent with a recent report that suggests that 
the major source of CXCL12 within the bone marrow is not mature osteoblasts (70). 
G-CSF treatment reduces the number of bone marrow myeloid dendritic cells. 
We recently reported that G-CSF treatment results in the loss of both inflammatory and 
resident monocytes from the bone marrow (85). In this study, we observed that G-CSF treatment 
also results in the loss of myeloid dendritic cells from the bone marrow (Figure 3.5). Whether the 
loss of these various monocytic subtypes occurs as a result of mobilization into the periphery or 
cell death in the marrow itself is unclear and remains an area of active investigation.  
DISCUSSION 
The cell types important for retaining HSPCs within the marrow and which are directly 
targeted by G-CSF in the initiation of the mobilization cascade are not well-defined. We and 
others recently identified a key role for monocytic cells in both of these processes (40,41,85); 
however, the specific cell type(s) within this lineage that regulate these processes have still not 
been clearly identified. Within the monocytic lineage, there are three major cell types in the bone 
marrow: 1) bone marrow resident macrophages; 2) myeloid (or bone marrow-derived) dendritic 
cells; and 3) osteoclasts. The goal of this study was to examine the contribution of osteoclasts 
and myeloid dendritic cells to the retention of HSPCs in the marrow and initiating the 
mobilization cascade in response to G-CSF using a series of ablation models.  
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The role of osteoclasts in HSPC retention and response to G-CSF has been the subject of 
many studies over the past several years, often with conflicting results. The data which supports 
a role for osteoclasts in regulation of HSPC mobilization includes the observation that agents 
which activate osteoclasts (such as soluble RANKL) also elicit HSPC mobilization, while known 
triggers of HSPC mobilization – such as infection or stress – also activate osteoclasts (42,90). 
Conversely, several genetic models of osteoclast deficiency, such as PTP-epsillon-deficient 
females or CD45-deficient mice, also display a reduced mobilization response to G-CSF (42,91). 
In contrast, the data which suggests that osteoclasts do not play an important role in regulation of 
G-CSF-induced mobilization include a pair of studies which demonstrated that inhibition of the 
bone-resorbing capacity of osteoclasts (and perhaps induction of osteoclast apoptosis) leads to an 
augmented response to G-CSF (40,44). In this study, we report that osteoclast loss following 
OPG-Fc treatment does not result in spontaneous mobilization of HSPCs nor does it alter the 
mobilization response to G-CSF. We believe that this approach represents a significant 
improvement over previous models of osteoclast ablation, as OPG-Fc causes a transient but 
complete loss of osteoclasts during which measurements into phenomena such as G-CSF-
induced mobilization can be made without concern for the effects of adaptation that may have 
occurred as a result of long-term osteoclast loss. As with any pharmacologic agent, however, 
there is always concern for off-target effects, so we are currently working on a genetic model of 
osteoclast ablation involving mice with targeted deletion of RANK (RANK-/-). RANK-/- mice 
lack the ability to form mature osteoclasts; as a consequence, however, they develop 
osteopetrosis at a very young age (< 3 weeks) with a resulting disruption in their bone marrow 
architecture so severe that any studies into hematopoietic stem cell trafficking are compromised. 
We attempted to create RANK -/- chimeras by transplanting fetal livers from RANK-/- mice into 
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lethally-irradiated wild-type recipients with the expectation that as the hematopoietic 
reconstitution occurred, recipient-derived osteoclasts would die off and not be replaced. 
However, even at ten weeks post-transplant, a significant number of osteoclasts remained, 
making it difficult to interpret any effect on G-CSF-induced mobilization. To circumvent this 
difficulty, we plan to transplant liver cells from RANK-/- fetuses into lethally-irradiated mice 
with targeted deletion of G-CSF receptor (G-CSFR-/-). As hematopoietic reconstitution occurs, 
no new osteoclasts would form because of the lack of RANK expression on donor-derived 
osteoclast precursors, while any residual recipient osteoclasts would be insensitive to G-CSF. 
The initial characterization of RANK-/- mice revealed that, in addition to a failure to develop 
mature osteoclasts, the mice have deficits in lymph node formation, but that hematopoiesis is 
otherwise unaltered (87). If osteoclasts are not required for G-CSF-induced mobilization, as 
suggested by the results of the OPG-Fc osteoclast ablation experiments, we would predict that 
reconstitution of a G-CSFR-/- mouse with RANK-/- marrow will be sufficient to restore a 
normal mobilization response to G-CSF. 
In contrast to osteoclasts, little is known about the role of myeloid dendritic cells in 
regulation of G-CSF-induced mobilization. In these studies, we observed that induction of 
myeloid dendritic cell ablation during the first half of the G-CSF treatment regimen actually 
increases the mobilization response to G-CSF and that myeloid dendritic cell ablation in itself 
suppresses osteoblasts without a corresponding suppression of CXCL12 production. This is 
consistent with the hypothesis that myeloid dendritic cells are not required for G-CSF-induced 
mobilization. Definitive evidence of this, however, requires an experimental paradigm similar to 
that used for the OPG-Fc osteoclast ablation experiments, wherein both myeloid dendritic cell 
and HSPC frequency can be measured throughout the course of G-CSF administration. 
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Although further study is required to elicit the exact mechanisms of the observations 
reported here, the available data suggest a model in which, at steady state, different cell types 
provide support to distinct stromal cell populations, such as mature osteoblasts and CXCL12-
abundant reticular (CAR) cells, which, in turn, facilitate retention of HSPCs within the marrow. 
Ablation of a single monocyte population leads to loss of one of the supported stromal cell 
populations, but there is sufficient redundancy within the system such that release of HSPCs into 
the periphery is not observed until multiple pathways are targeted. Agents such as G-CSF or 
clodronate-loaded liposomes target multiple pathways, leading to changes in a number of the 
important retention molecules and ultimately leading to mobilization of HSPCs. This model is 
also consistent with a role for sympathetic nervous system neurons in regulation of G-CSF-
induced mobilization, as Katayama, et al. reported that G-CSF can act via sympathetic nervous 
system neurons to regulate osteoblast survival (21). As the number of defined cell populations 
has increased, it has become clear that a detailed understanding of the mechanisms involved in 
regulating stem cell trafficking will require a careful dissection of the contributions of each of 
the identified populations. 	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FIGURES 
Figure 3.1 
	  
 
Osteoclast loss does not lead to mobilization of HSPCs. Wild-type mice were given a single 
dose of 100 µg OPG-Fc on day 0. At the time point indicated, they were sacrificed and the 
frequency of (A) KLS cells or (B) colony-forming units [CFU-Cs] was measured. None of the 
peripheral blood or spleen KLS or CFU values were significantly different than the day 0 value 
using a one-way ANOVA with Dunnett’s post-test to correct for multiple comparisons. The data 
indicate that osteoclast ablation using OPG-Fc is not sufficient to release significant numbers 
HSPCs into the peripheral circulation n = 2-3 mice per day.  	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Figure 3.2 
 
Osteoclasts are not required for G-CSF-induced mobilization of HSPCs. Mice received 
combinations of G-CSF and OPG-Fc as indicated; at the conclusion of the treatment period, mice 
were sacrificed and the frequency of KLS cells (A) or colony-forming units [CFU-Cs] (B) was 
measured. The data indicate that pre-treatment with OPG-Fc for a duration sufficient to ablate 
osteoclasts does not alter the mobilization response to G-CSF. n = 2-5 animals per group. 	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Figure 3.3 
 
	  
Ablation of myeloid dendritic cells augments the mobilization response to G-CSF. Chimeras 
of mice carrying the CD11c-DTR transgene or their non-transgenic littermates were constructed. 
Once reconstitution had occurred, the mice received a combination of diphtheria toxin and G-
CSF as indicated in panel (A). At the end of the treatment period, the animals were sacrificed 
and the frequency of KLS cells (B) and colony-forming units [CFU-C] (C) in the peripheral 
blood, bone marrow, and spleen were measured. n = 4 animals per donor genotype per treatment 
group. 	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Figure 3.4 
 
	  
Ablation of myeloid dendritic cells augments the G-CSF-induced peripheral leukocytosis 
and suppression of mature osteoblasts but not total bone marrow CXCL12 production. 
Chimeric mice were constructed as described in Figure 3.3. (A) The concentration of white blood 
cells in the periphery was measured using an automated cell counter. (B,C) RNA was isolated 
from tibial flushes and assayed for expression of osteocalcin (B) or CXCL12 (C). The effect of 
G-CSF treatment on each parameter was compared between CD11c-DTR chimeras and non-
transgenic chimeras using a two-way ANOVA; p < 0.05 for white blood cell counts and 
osteocalcin expression; p = 0.31 for CXCL12 expression. Pairwise comparisions were made 
using Bonferroni’s post-test to correct for multiple comparisons or the Student’s t-test where 
appropriate. **p < 0.01, ***p < 0.001. n = 4 mice per donor genotype per treatment group. 	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Figure 3.5 
	  
G-CSF administration reduces the frequency of myeloid dendritic cells in the bone 
marrow. Chimeras constructed as previously described received diphtheria toxin and G-CSF 
according to the schematic in Figure 3.3A. At the end of the treatment period, the frequency of 
myeloid dendritic cells (CD11chiMHC Class IIhi) was assayed using flow cytometry. n = 4 mice 
per donor genotype per treatment group. 	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Supplemental Figure 3.1 
	  
 
Administration of a single dose of 100 µg OPG-Fc is sufficient to ablate osteoclasts. Mice 
were treated with a single dose of 100 µg OPG-Fc via subcutaneous injection (panels C-E) or left 
untreated (panels A,B). Seven days later, the animals were sacrificed; sections were prepared and 
stained for tartrate-resistant acid phosphatase (TRAP) activity and counterstained with 
hematoxylin. Each panel represents a section from an individual mouse. 	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Supplemental Figure 3.2 
	  
Inhibition of osteoclast activity with zoledronate (Zometa) results in mobilization and 
augments the mobilization response to G-CSF without a significant reduction in the 
frequency of TRAP+ cells. (A) TRAP-stained section of femur from untreated and zoledronate-
treated animals. (B) Effect of zoledronate on frequency of KLS cells, both alone and in 
combination with G-CSF. n = 2-3 animals per group. 
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CHAPTER 4 
SUMMARY AND FUTURE DIRECTIONS 
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Monocytic-lineage cells are directly targeted by G-CSF in the initiation of hematopoietic 
stem and progenitor cell mobilization.  
The long-term goal of these studies was to understand the regulation of hematopoietic 
stem cell (HSC) trafficking as a prerequisite to the development of novel mobilizing agents.  Our 
approach was to probe the mechanism by which granulocyte-colony stimulating factor (G-CSF), 
a hematopoietic growth factor considered to be the best available mobilizing agent, elicits 
mobilization of hematopoietic stem and progenitor cells (HSPCs). Our studies were focused on a 
very basic question: what cell type is first targeted by G-CSF in the initiation of HSPC 
mobilization? 
Previously published data from our lab demonstrated that the cell type targeted by G-CSF 
was contained within the transplantable hematopoietic compartment, as chimeric mice bearing 
wild-type hematopoietic cells in the background of a G-CSF receptor (G-CSFR)-deficient stroma 
exhibited a normal mobilization response to G-CSF (23). Within the transplantable 
hematopoietic compartment, there are four major cell types/lineages with known expression of 
the G-CSF receptor: neutrophils, monocytes, lymphocytes/NK cells, and HSCs. In Chapter 2, we 
systematically evaluated the importance of each of these lineages to G-CSF-induced 
mobilization. We report that in two different mouse models of lymphocyte deficiency, G-CSF-
induced mobilization is normal, suggesting that lymphocytes and NK cells are not directly 
targeted by G-CSF. We also report that in chimeric mice containing various mixtures of wild-
type and G-CSFR-deficient neutrophils, the mobilization response to G-CSF is poorly correlated 
with the frequency of wild-type neutrophils, suggesting that neutrophils are also not directly 
targeted by G-CSF. Lastly, we engineered a transgenic mouse model in which expression of G-
CSF receptor was limited to monocytic cells and demonstrated that the mobilization response to 
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G-CSF was normal in these animals, suggesting that G-CSF signaling in monocytic cells was 
sufficient for a normal mobilization response.  
We also reported that bone marrow macrophages promoted survival of mature osteoblasts 
in an in vitro co-culture system and that in response to G-CSF there was a loss of monocytic cells 
– specifically inflammatory and resident monocytes – from the bone marrow. Previously 
published data from our lab and others had identified osteoblast suppression as part of the 
response to G-CSF (21,64,66,67), while Visnjic, et al reported that transient ablation of 
osteoblasts was sufficient to elicit HSPC mobilization (53). Together with data demonstrating 
that loss of monocytic cells was sufficient to elicit HSPC mobilization (40,41), these data 
suggested a model in which monocytic cells promoted the retention of HSPCs within the marrow 
through their support of mature osteoblasts. In response to mobilizing agents such as G-CSF, the 
monocytic cells are lost from the marrow, thereby reducing support for osteoblasts. These 
osteoblasts undergo apoptosis, ultimately leading to release of HSPCs into the periphery. 
Whether the loss of monocytic cells from the marrow is the result of apoptosis or mobilization 
into the periphery remains an area of active investigation.  
Osteoclasts are not required for G-CSF-induced mobilization, while myeloid dendritic cells 
regulate osteoblast survival without altering bulk CXCL12 levels 
With the identification of monocytic cells as critical to both retention of HSPCs within 
the marrow and the mobilization response to G-CSF, we shifted our focus to identifying the 
contributions of the various cell types within this lineage. In the bone marrow, there are three 
major subtypes of monocytic cells: bone marrow macrophages, myeloid dendritic cells, and 
osteoclasts. Data from Chow, et al. suggested that loss of bone marrow macrophages using a 
CD169-DTR ablation model resulted in mobilization of HSPCs (41), although the effect of 
ablation on G-CSF-induced mobilization was not reported. While it is clear that a population of 
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bone marrow macrophages express CD169 and were therefore likely depleted in Chow, et al.’s 
paradigm, there appear to be other bone marrow populations such as granulocytic precursors that 
also express CD169 and were hence also ablated, confounding the data interpretation. The ability 
to selectively ablate bone marrow macrophages remains a formidable technical challenge. 
In Chapter 3, we continued the evaluation of monocytic subtypes, evaluating the role of 
myeloid dendritic cells and osteoclasts both in HSPC retention and in G-CSF-induced 
mobilization. As mentioned in Chapter 3, the role of osteoclasts in HSPC trafficking has been 
debated over the past several years using a variety of different pharmacologic agents and genetic 
systems to reduce or ablate osteoclast function. As with bone marrow macrophages, the complete 
ablation of osteoclasts without major disruption of bone marrow architecture has proved to be a 
technical challenge. We used a recombinant form of osteoprotegerin conjugated to a Fc 
immunoglobulin fragment (OPG-Fc, a generous gift of Amgen, Inc.) to induce a complete but 
transient ablation of osteoclasts in mice and measured the effect both on HSC retention and on 
the mobilization response to G-CSF. We report that the loss of osteoclasts does not result in 
constitutive mobilization of HSPCs, nor does it alter the mobilization response to G-CSF. We are 
currently working on a genetic model of osteoclast loss (described in Chapter 3) to complement 
the data from the OPG-Fc ablation model.  
We also evaluated the role of myeloid dendritic cells using a diphtheria toxin-based 
transient ablation model (93). Our preliminary findings suggest that loss of myeloid dendritic 
cells is not sufficient to release HSPCs into the periphery, although a more extensive time course 
of dendritic cell depletion is underway to confirm these findings. Surprisingly, we observed that 
ablation of myeloid dendritic cells appears to augment the mobilization response to G-CSF. The 
mechanistic basis for these observations is as yet unclear, although it is unlikely that myeloid 
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dendritic cells are required for G-CSF-induced mobilization. We also observed that ablation of 
myeloid dendritic cells leads to a decrease in expression of osteocalcin – a marker of mature 
osteoblasts – without a corresponding drop in CXCL12 production, consistent with an earlier 
report suggesting that the mature osteoblasts are not the major source of CXCL12 in the bone 
marrow (70). 
In summary, we have presented data that suggests that G-CSF acts on monocytic cells to 
initiate the HSPC mobilization cascade and that monocytic cells promote retention of HSPCs 
within the marrow. Our initial model was that a single member of the monocytic lineage 
provides trophic support to mature osteoblasts or osteoblastic precursors, which in turn secrete 
factors (such as CXCL12) that promote retention of HSPCs in the marrow. Agents such as G-
CSF direct the monocytic cell population to reduce trophic support for osteoblasts, leading to 
their apoptosis and release of HSPCs into the periphery. In line with this model, we focused our 
attention on identifying which cell type within the monocytic lineage fulfilled this role. 
However, the data from the myeloid dendritic cell ablation studies as well as the data 
demonstrating that the majority of CXCL12 in the marrow comes from cells other than mature 
osteoblasts or osteolineage cells suggests that the biology may be more complicated than initially 
believed. Our current thinking is that multiple monocytic populations provide trophic support to 
different stromal populations including osteoblasts and CXCL12-abundant reticular (CAR) cells, 
each of which contributes to regulation of HSPC trafficking. Agents such as G-CSF or 
clodronate affect multiple monocytic cell types, which, in turn, leads to changes in different 
stromal populations, the culmination of which is the release of HSPCs into the periphery. The 
regulation of trafficking is fine-tuned even further by the sympathetic nervous system and/or 
nestin+ mesenchymal stem cells, as has been suggested by work from the Frenette group 
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(21,73,98). A detailed understanding of the mechanism is likely to require isolation of individual 
cell populations and characterization of their function. 
Identification and characterization of factors used by monocytic cells to support stromal 
populations important for HSPC retention 
The next major challenge awaiting investigators in this field is the identification of the 
factor or factors used by monocytic cells to support stromal populations, the so-called ‘factor X.’ 
It has been long understood that macrophages can provide trophic support to osteoblasts (74,75), 
but the importance of such a secreted factor in regulation of HSPC trafficking was not 
appreciated until 2000, when it was observed that G-CSF mobilized wild-type and G-CSFR-/- 
HSPCs with equal efficiency in a mixed chimera model (23), but the nature of the factor has 
remained elusive. This factor is likely to be of great interest in the development of novel 
mobilizing agents, as disruption of its signaling should be sufficient to suppress the stromal 
populations critical for HSPC retention within the marrow.  
We reported that macrophages provided robust trophic support for osteoblasts in a co-
culture system, but that the effect was diminished – although not eliminated – if the osteoblast 
and macrophage layers were separated by a semi-permeable membrane (85). The trophic effect 
on osteoblasts could not be sustained using macrophage-conditioned media, however, suggesting 
that the factor was likely to be labile and hence needed to be continually produced by the 
macrophages. In a similar experiment, Chow, et al. demonstrated that macrophage-conditioned 
media could stimulate production of CXCL12 by MS-5 stromal cells, and that pre-incubation of 
the media with proteinase K abrogated this effect (41). These data suggest that the factor 
involved is a secreted protein. Using a series of antibodies to neutralize the candidate factor or 
macrophages isolated from animals with genetic deletion of the candidate factor, Chow, et al 
evaluated the ability of IGF-1, IL-1, TNF-alpha, and IL-10 to promote CXCL12 production by 
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MS-5 stromal cells. Unfortunately, individual neutralization of the factors listed did not appear to 
have any impact on stromal cell production of CXCL12. 
Our initial model of the relationship between monocytic cells and osteoblasts predicted 
that monocytic cells would reduce production of trophic factors for osteoblasts following 
exposure to G-CSF. To identify candidate trophic factors, therefore, our lab isolated CD115+ 
from the bone marrow of mice before and after G-CSF treatment. Since osteoblast suppression 
begins within 48 hours after the onset of G-CSF treatment (66,67), we isolated CD115+ cells  at 
3 and 16 hours after exposure to G-CSF and subjected them to expression profiling. Three 
different experiments were performed and the data was analyzed in two different ways: first, the 
data was analyzed in an unbiased fashion using the significance analysis of microarrays (SAM) 
algorithm. Using this approach with a false discovery rate of 10%, 15 genes were found to be 
either upregulated or downregulated. Of these, only one – IGFBP6 – has a described role in 
regulation of bone metabolism. Next, the data was analyzed in a biased fashion, tracking only the 
expression of 53 genes with known roles in regulation of osteoblasts. Of these, only six were 
expressed at a level detectable by the array. These genes are shown in Table 1 (courtesy of D. C. 
Link). 
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We used quantitative PCR analysis to confirm that the changes in expression of each of 
these genes was not simply the result of probe failure. To determine whether these changes in 
mRNA levels reflected changes in protein expression, we isolated bone marrow extracellular 
fluid from mice that had been treated with G-CSF for varying amounts of time1 and analyzed the 
concentration of candidate factors using ELISAs. Because the most significant changes in 
expression were observed for osteopontin and IGFBP6, we focused our attention on those first.  
Monocyte-derived osteopontin is not required for G-CSF-induced mobilization 
Osteopontin (OPN, gene name Spp1) is a cell-surface glycoprotein primarily expressed 
by osteoblasts. There is no direct evidence implicating osteopontin in osteoblast survival; in fact, 
Spp1-/- mice have normal osteoblast numbers and morphology (59). There are a number of 
studies, however, suggesting a role for osteopontin in regulation of HSPC trafficking and 
maintenance of HSPC quiescence, including one study demonstrating that Spp1-/- mice exhibit 
constitutive mobilization (60,61,99-101). In response to G-CSF, the concentration of osteopontin 
in the bone marrow 3 days after G-CSF treatment was approximately 2.5-fold higher than in 
untreated mice, consistent with the changes in RNA expression noted on the microarray data 
(data not shown).   
To test the importance of the rise in monocyte-derived osteopontin in G-CSF-induced 
mobilization, we transplanted marrow from Spp1-/- mice into lethally-irradiated wild-type 
recipients. Once reconstitution had occurred, the mice were treated with a seven-day course of 
G-CSF, after which the mobilization response was measured. We predicted that if an increase in 
monocytic osteopontin was important for G-CSF-induced mobilization, the Spp1-/- chimeras 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 Mice were sacrificed by exposure to carbon dioxide and the femurs were dissected out. The patellar cap was 
removed and the marrow extracted from the femurs by centrifugation at 3,300 x g for 1 minute at room temperature. 
The resulting mixture of bone marrow cells and extracellular fluid was resuspended in 300 µL PBS. The cellular 
component was separated out by centrifugation at 3,300 x g. The resulting supernatant was used for ELISA. 
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would mobilize poorly, if at all. Unlike Spp1-/- mice, the Spp1-/- chimeras did not display 
constitutive mobilization, and their mobilization response to G-CSF was normal (data not 
shown). These data suggest that an increase in monocyte-derived osteopontin is not required for 
G-CSF-induced mobilization. Based on these data, we decided to abandon further exploration of 
the role of this protein in regulation of HSPC trafficking. 
Monocytes may influence osteoblast survival through modulation of IGF signaling 
Insulin-like growth factor binding protein 6 (IGFBP6) is a key regulator of IGF signaling. 
It is known to bind insulin-like growth factors (IGFs), preventing them from signaling through 
IGF receptors. The insulin-like growth factors IGF-I and IGF-II are anabolic peptides with 
described roles in promoting osteoblast survival (reviewed in (102)). The expression profiling of 
monocytic cells shown above revealed both an increase in IGFBP6 expression along with a 
decrease in IGF-I expression, suggesting an overall suppression of IGF-I signaling. By ELISA, 
the concentration of IGFBP6 in bone marrow extracellular fluid increased four-fold over baseline 
at 24 hours after G-CSF treatment, returning to twice the baseline value by 72 hours and 
remaining there for the next four days, consistent with the changes observed by microarray.  
To evaluate the importance of IGFBP6 levels in regulation of HSPC trafficking, we are 
preparing a lentiviral construct with tetracycline-inducible expression of IGFBP6. We will infect 
bone marrow from mice expressing a tetracycline transactivator under the Rosa26 promoter 
(Rosa-tTA) and transplant these cells into lethally-irradiated mice. Once reconstitution has 
occurred, we will induce expression of IGFBP6 in the hematopoietic compartment. We predict 
that if the increase in IGFBP6 levels is an important element of the response to G-CSF, induction 
of IGFBP6 should result in constitutive mobilization.  
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We have also obtained a mouse in which the Igf1 locus is surrounded by loxP sites. We 
are crossing this mouse with one expressing Cre recombinase under the control of a tamoxifen-
inducible promoter (ERT2-Cre). Marrow from offspring homozygous for the floxed Igf1 allele 
and carrying the ERT2-Cre transgene will be transplanted into lethally-irradiated wild-type mice. 
Once reconstitution has occurred, Cre recombinase expression will be induced, thereby 
diminishing production of IGF-I by hematopoietic cells. We predict that if hematopoietically-
derived IGF-I is important for osteoblast survival, the induction of IGF-I deletion will result in 
osteoblast apoptosis and HSPC mobilization. 
Finding the next set of candidates for ‘Factor X’ 
The identification of factors present in the bone marrow extracellular fluid that may 
regulate survival of osteoblasts is a formidable technical challenge. We are currently exploring 
new approaches to identifying candidates for ‘factor X.’ One approach that we are considering is 
expression profiling of monocytic subpopulations. Preliminary data from our lab suggests that 
monocytic cells are lost from the bone marrow in response to G-CSF; we are currently tracking 
the frequency of various monocytic subpopulations using an approach similar to the one 
described by Chow, et al. (41) to determine if one of the subpopulations changes more 
dramatically than the others in response to G-CSF. If so, expression profiling of this 
subpopulation may identify additional candidates for ‘factor X.’ In addition, we are considering a 
proteomic analysis of bone marrow extracellular fluid before and after G-CSF treatment; 
however, only a small fraction of proteins can be analyzed in this fashion. 
Conclusion 
In this work, we report that monocytic cells are essential both for HSPC retention within 
the marrow but also for G-CSF-induced HSPC mobilization. Short-term efforts will be focused 
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on clarifying the roles of the various monocytic subtypes in this process, but the development of 
novel mobilizing agents will likely require the identification of factors important for 
communication between monocytic cells and the stromal populations which regulate HSPC 
retention. 	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